Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination by De Costa, Anna-Maria Alicia
Medical University of South Carolina 
MEDICA 
MUSC Theses and Dissertations 
2012 
Premalignant Oral Lesion Immunobiology: Immune Modulation 
and Vaccination 
Anna-Maria Alicia De Costa 
Medical University of South Carolina 
Follow this and additional works at: https://medica-musc.researchcommons.org/theses 
Recommended Citation 
De Costa, Anna-Maria Alicia, "Premalignant Oral Lesion Immunobiology: Immune Modulation and 
Vaccination" (2012). MUSC Theses and Dissertations. 614. 
https://medica-musc.researchcommons.org/theses/614 
This Dissertation is brought to you for free and open access by MEDICA. It has been accepted for inclusion in 
MUSC Theses and Dissertations by an authorized administrator of MEDICA. For more information, please contact 
medica@musc.edu. 
Premalignant Oral Lesion 
Immunobiology: 
Immune Modulation and Vaccination 
by 
Anna-Maria Alicia De Costa 
A dissertation submitted to the faculty of the Medical University of 
South Carolina in partial fulfillment of the requirements for the degree 
of Doctor of Philosophy in the College of Graduate Studies 
Department of Microbiology and Immunology 
Dr. M. Rita I. Young 
Graduate committee 
chairperson 
Dr. Amanda LaRue 
Dr. Shikhar Mehrotra 






Dr. Steven Rosenzweig Date: () ~/" I z.. 
Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination 
ACKNOWLEDGEMENTS 
The work described in this dissertation has required a great deal of 
perseverance and could not have been accomplished without the love and support 
of friends and family. The author would like to thank her husband, Brian De Costa, 
and mother, Josephine a'Ryan for their unremitting encouragement, love, and 
support throughout the author's graduate career. Many thanks also go out to the 
rest of the Clark, De Costa, and O'Ryan families, especially the author's brother and 
sister-in-law, Carl and Anne Clark. 
The research presented here has also been supported by the technical 
support of Corinne Schuyler, Kim Sutton, Kiwana Gibbs and Bridgette Ransom, as 
well as the friendship and encouragement of fellow students Danielle Justis, Jarrett 
Walsh, and Jennifer Mulligan. The expertise of fellow student Adam Mailloux has 
been especially helpful in the accomplishment of this research. 
Many thanks are also owed to the author's committee, Drs. Amanda LaRue, 
Shikhar Mehrotra, Christopher Parsons, and Steven Rosenzweig. Their ongoing 
assistance has been essential in making this dissertation possible. 
Finally, the author would like to express her abiding gratitude to Dr. Rita 
Young. Her mentorship, not only in research but also in life, has been invaluable, 
and her friendship will always be treasured. As such, the author would like to 
dedicate this dissertation to Dr. Young. 
ii 



















LIST OF FIGURES 
37 
...................................................................................... , ... ... ... ... ... ... ... ...... 40 
............................................................. "............................................................... 41 
................................................... ............... ..................... ....................... .... 43 
......... .......................................................................................... ........... .... 45 
47 
........................ ............................................. ......................................... .... 48 









... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...... ... ... ...... ... ... ... ... ... ... ... ... ... ... ... ......... 82 
...... .......................................... ........................... ................................ .... 85 
iii 
Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination 
LIST OF ABBREVIATIONS 
/ .......... ,. ... .... Homozygous genetic knockout 
4NQO ...... ........ 4-nitroquinoline 1-oxide 
4NQO Ctl........ 4NQO-treated control mice 
ARG.... ... ...... .... Arginase 
ATP ... ...... ... ..... Adenosine triphosphate 
BeA... ...... ....... Bicinchoninic acid 
BM ...... u....... ... Bone marrow 
CBA... ... ... ... .... Cytokine bead array 
CD ................ .... Cluster of differentiation 
CFSE............... Carboxyfluorescein succinimidyl ester 
COX-2............. Cyclooxygenase-2 
CTL................. Cytotoxic T lymphocyte 
CTLA-4........... Cytotoxic T-Iymphocyte antigen 4 
DC ...... ... ...... .... Dendritic cell 
Dent......... ... ... Normal tongue epithelium lysate-pulsed dendritic cells or mice 
vaccinated with these cells 
DCpm ...... ~...... Premalignant tongue epithelium lysate-pulsed dendritic cells or 
mice vaccinated with these cells 
EGFR...... ... ..... Epidermal growth factor receptor 
FasL................ Fas ligand 
FBSn............... Fetal bovine serum 
Foxp3 ... .......... Forkhead box protein 3 
GAGE.............. G antigen 
GM-CSF.......... Granulocyte macrophage colony stimulating factor 
iv 
Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination 
HBSS............... Hank's balanced salt solution 
HNSCC............ Head and neck squamous cell carcinoma 
HPV................ Human papillomavirus 
IFN-y.............. Interferon-y 
IL............... ..... Interleukin 
KLRG1............ Killer cell lectin-like receptor subfamily G member 1 
LN ... ...... ....... ... Lymph node 
LPS...... ........... Lipopolysaccharide 
MDSC.............. Myeloid-derived suppressor cell 
MHC............... Major histocompatibility complex 
MIP ... ... ... ........ Macrophage inflammatory protein 
MUC-l............ Mucin 1, cell surface associated 
NK cell............ Natural killer cell 
NY -ESO-1... .... Cancer-testis antigen 
PD-1............... Programmed death 1 
PD-Ll............. Programmed death ligand 1 
PG E2............... Prostaglandin E2 
PM ...... ... ... ... ... Premalignant 
PMA...... ... ... ... Phorbol 12-myristate l3-acetate 
RAG................ Recombination activating gene 
RAGE.............. Renal tumor antigen 
RANTES......... Regulated upon activation, normal T cell expressed, and secreted 
SCID ... ... ... ... ... Severe-combined immune defiCiency 
v 
Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination 
SEM... ... ....... ... Standard error of the mean 
TAA................ Tumor-associated antigen 
TAM ............... Tumor-associated macrophage 
Tel... ... ... ... ...... IFN -v-producing cytotoxic T -lymphocyte 
Tel7............... IL-l7-producing cytotoxic T-Iymphocyte 
Teonv............. Conventional T cell 
TGF-J3............. Transforming growth factor-J3 
Th1................. Type 1 helper T-Iymphocyte 
Th2 ...... ... ........ Type II helper T -lymphocyte 
Th17............... IL-17-producing helper T-Iymphocyte 
TIL.................. Tumor infiltrating lymphocyte 
TNF ... .......... ... Tumor necrosis factor 
TRAIL...... ... .... Tumor necrosis factor-related apoptosis-inducing ligand 
Treg................ Regulatory T cell 
VEGF ............... Vascular endothelial growth factor 
WT ......... ......... Wild type 
vi 
Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS............................................................................................. ii 
LIST OF FIGURES......................................................................................................... iii 
LIST OF ABBREVIATIONS........................................................................................... iv 
ABSTRACT ............................. , ... ... ... ... ......... ... ... ... .................. ... ...... ... .............................. ix 
CHAPTER 1. IMMUNOEDITING AND HNSCC.................................................................... 1 
1.1 An Introduction to Immunoediting...... ...... .............. .................. ........ 2 
1.1.1 Elimination and Equilibrium.................................................. 2 
1.1.2 Immune Escape ...................................................................... , 3 
1.1.3 Inflammation as a Tumor-Promoting Mechanism............... 6 
1.2 Immune Reactivity Potential Towards HNSCC............... ......... ......... 9 
1.3 HNSCC-Induced Defects in Immune Function................................... 11 
1.3.1 Avoiding Immune Detection and Destruction....................... 11 
1.3.2 HNSCC-Derived Soluble Immune Inhibitory Mediators...... 11 
1.3.3 HNSCC Induction of Immune Suppressive Cells.................... 12 
CHAPTER 2. RATIONALE, HYPOTHESIS, AND SPECIFIC AIMS.............................. 16 
2.1 Rationale.................................................................................................. 17 
2.1.1 Hypothesis................................................................................. 19 
2.1.2 Specific Aims.............................................................................. 19 
2.2 SIgnIfIcance.............................................................................................. 20 
CHAPTER 3. IMMUNE RESPONSE TO HNSCC DEVELOPMENT.............................. 22 
3.1 Introduction............................................................................................ 23 
3.2 Materials and Methods........................................................................... 28 
3.3 Results..................................................................................................... 33 
3.4 Discussion............................................................................................... S1 
CHAPTER 4. DENDRITIC CELL VACCINATION OF PREMALIGNANT LESION-
BEARING MICE............................................................................................................ 56 
4.1 Introduction............................................................................................ 57 
4.2 Materials and Methods........................................................................... 61 
4.3 Results..................................................................................................... 66 
4.4 Discussion............................................................................................... 81 
CHAPTER 5. GENERAL DISCUSSION ............ ...... ......... ............ .................... .............. 87 
5.1 Implications of Immune Response During HNSCC Development.. ..... 88 
5.2 Complexity of HNSCC-Associated Immune Response......................... 89 
vii 
Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination 
5.3 Immunotherapy at the Premalignant Stage......................................... 92 
5.4 Closing Remarks..................................................................................... 94 
LIST OF REFERENCES................................................................................................. 96 
viii 
Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination 
ABSTRACT 
While studies have indicated that squamous cell carcinoma of the head and 
neck (HNSCC) is associated with immune suppression, these studies did not analyze 
the immune response at the dysplastic stage. This study utilized a mouse model of 
4-nitroquinoline 1-oxide (4NQO)-induced oral carcinogenesis to examine the 
alterations in immune phenotype at the premalignant and malignant stages of 
HNSCC. Cervical lymph nodes of HNSCC-bearing mice were found to contain a 
greater number of cells, including a greater number of conventional (Tconv) and 
regulatory (Treg) T cells, compared to lymph nodes of control and premalignant 
lesion-bearing mice. Premalignant lesion-bearing mouse lymph nodes consist of a 
greater percentage of Tconv cells expressing markers for activation, memory, and 
exhaustion compared to both control and HNSCC-bearing mice. Lymph nodes from 
both premalignant lesion-bearing and HNSCC-bearing mice include increased 
numbers ofThl, Tcl and Th17 cells compared to control mice. The data show that 
while there is the expected increase in Tregs in lymph nodes when HNSCC is 
present, there is also an unexpected increase in immune populations usually 
associated with a beneficial anti-tumor response. In addition, the results 
demonstrate that the premalignant stage of HNSCC development is associated with 
a robust immune response involving an increase in inflammatory cells. 
The use of dendritic cell (DC) vaccines as treatment for malignancy is 
complicated by the immune evasion tactics often employed by carcinomas such as 
HNSCC. This study aims to determine if an immune response can be elicited by 
administering a DC vaccine during the premalignant stages of HNSCC, prior to 
ix 
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development of immune escape. Bone marrow-derived DCs were pulsed with 
premalignant lesion lysate (OCpm) and administered to 4NQO-treated mice 
exhibiting premalignant lesions. Endoscopic examination revealed that DCpm 
vaccination and control vaccination with dendritic cells pulsed with normal tongue 
epithelium lysate (Dent) significantly decreased lesion burden. Analysis of lymph 
node cells revealed that while Dent vaccination resulted in a rapid increase in total 
lymphocyte count, levels of activated Tconv cells, and Thl, Tel, Th17, Tcl7, and Th2 
cells, DCpm vaccination results in a delayed, yet substantial, increase in these 
immune effector mechanisms. This suggests that dendritic cell vaccination may 
have a beneficial effect on clinical outcome regardless of type of antigenic 
stimulation, and DCs pulsed with premalignant lysate rather than normal tongue 
epithelium lysate result in a delayed immune effector response upon vaccination of 
premalignant lesion-bearing mice. 
x 
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CHAPTER 1: IMMUNOEDITING AND HNSCC 
1.1 An Introduction to Immunoediting 
1.1.1 Elimination and Equilibrium 
The classic theory of immunoediting describes the incredibly complex 
immune interactions with dysplastic tissue during and after the development of 
cancers. In the first stage of immunoediting known as elimination, immune cells 
patrol the body, recognizing transformed cells and eliminating them through a 
reaction that traditionally is described as involving Thl cells which direct CD8+ 
cytotoxic T cells (CTLs) and macro phages to clear the dysplastic tissue (1, 2). 
Evidence for this inc,ludes research showing that mice with either severe-combined 
immune-deficiency (SCID) or lack of recombination activating gene (RAG-I-), leading 
to absence of T cells, B cells, and NK cells .. are more susceptible to chemically-
induced tumors than wild type (WT) controls (1 .. 3, 4). Humans with 
immunodeficiencies are also at an increased risk for carcinogenesis, whether the 
cancers are of a viral or non-viral etiology (5-9). The type 1 response was identified 
as the main effector mechanism of tumor immunosurveillance after it was found 
that mice with specific deletions of CD4+ and/or CD8+ cells, antibody-mediated 
neutralization or knockout of IFN-y, or knockout of IL-12 .. perforin or TRAIL all have 
increased incidence and/or growth of several different types of cancer (2, 10-16). 
Despite the evidence for beneficial immune responses against dysplastic 
tissue .. sometimes the tissue is not sufficiently cleared. If the initial transformation 
results in weakly immunogenic tissue, then it may avoid detection, moving into the 
equilibrium phase of immunoediting. During this stage, immunogenic variants that 
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arise may be targeted and eliminated by the immune system, while less 
immunogenic variants that develop mutations making them more resistant to 
immune effector mechanisms survive to multiply. In effect, the combination of time 
and the selective pressure of the immune system on cells that are prone to 
accumulate mutations to a greater degree than healthy cells results in the 
emergence of tumor variants that have been shaped to completely avoid elimination 
by the immune system (17-19). 
1.1.2 Immune Escape 
Tumor variants emerging from the process of immune equilibrium lose all 
immunogenicity and develop methods of manipulating the immune system for the 
tumor's benefit. This last stage of immunoediting is referred to as escape. 
Established tumors have been shown to avoid immune recognition through 
downregulation of immunogenic markers and/or MHC class I molecules (20, 21). 
Malignancies can also combat immune destruction by sabotaging an antitumor 
immune response through direct and indirect upregulation of immunosuppressive 
cells and downregulation of immunostimulatory cells. 
As indicated before, a type I reaction, in which Thl cells initiate cell-based 
immune responses involving various immune effectors, is considered necessary for 
a beneficial anti-tumor immune response to occur. In tumor escape, tumors develop 
the ability to downregulate the type I effector response and upregulate a type II 
effector response which, while beneficial under certain conditions, is most often 
associated with a poor prognosis in cancer patients. Interleukin-12 and IFN-y, both 
Chapter 1 3 Immunoediting and HNSCC 
Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination 
type I cytokines, have been found in reduced levels in multiple types of cancers (22-
24). Reduced IL-12 in cancer patients has been associated with reduced numbers of 
CTLs, and reduced IFN-y has been shown to reduce induction of MHC class I and 
class II and directly induce T cell anergy (25-27). 
In contrast to type I cytokines, the type II cytokines IL-4, IL-I0, and TGF-~ 
have all been shown to be upregulated in patients with many types of advanced 
cancers (22-24, 28, 29). IL-4 directly inhibits Th1 cell differentiation, 
downregulates IFN-y production, and upregulates the type II response (30-34). Like 
IL-4, IL-10 downregulates IFN-y production (33). It has also been shown to reduce 
IL-12 production, downregulate MHC surface expression, and induce tumor-
associated T cell tolerance (35-38). TGF-~ affects the immune system in multiple 
ways: it has been shown to reduce differentiation, proliferation and functional 
capacity of T cells, including downregulation of a Thl response by inhibition of IL-2 
and IFN-y production in Thl cells and inhibition of FAS ligand and perforin 
expression in CTLs (39-45). TGF-~ also inhibits costimulation, antigen presentation, 
maturation, and IL-12 production in antigen presenting cells, further 
downregulating a type I response (46, 47). Finally, TGF-~ has been shown to 
increase tumor production of prostaglandin E2 (PGE2) and vascular endothelial 
growth factor (VEGF), which both promote tumor growth in multiple ways 
themselves (48-51). These changes in the cytokine milieu contribute a great deal to 
the blockade of a functional antitumor immune response in the microenvironment 
of many established tumors. 
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Many cancer types are also associated with an upregulation of 
immunosuppressive cells such as CD34+ progenitor cells, myeloid-derived 
suppressor cells (MDSCs), tumor associated macrophages (TAMs), and regulatory T 
cells (Tregs). The CD34+ progenitor cell refers to the earliest hematopOietic 
progenitor cell found in the circulation; these cells are found in low numbers in 
healthy individuals and in elevated numbers in both the circulation and tumor mass 
of cancer patients (52-55). These cells have been found to suppress T cell 
proliferation through the release ofTGF-~ (56, 57). MDSCs are less immature 
progenitor cells from the same lineage as C034+ progenitors; they too have been 
found to be elevated in various tissues of tumor-bearers, and their presence is 
associated with a poorer prognosis (58-60). These cells have been shown to directly 
suppress T cell responses and promote T cell apoptosis through production of ARGl 
and nitric oxide synthase and indirectly suppress T cell responses through 
production ofTGF-~ and IL-I0 (61-64). TAMs are mature myeloid cells that 
originated as circulating monocytes and have differentiated into type II 
macrophages in the tumor microenvironment. Like C034+ progenitor cells and 
MDSCs, they are upregulated in multiple tumor types and their upregulation is 
associated with a poor prognosis (65-67). Also like MDSCs, TAMs suppress T cell 
function through the production ofTGF-(3 and IL-10 (68-70). They also produce 
several growth factors, such as epithelial growth factor, platelet-derived growth 
factor, and basic fibroblast growth factor that can directly promote tumor growth 
(71, 72). Both CD34+ progenitor cells and MDSCs appear to be mobilized from the 
bone marrow and recruited to the site of the tumor by a combination of tumor-
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derived GM-CSF and VEGF (73-77). TAM differentiation is thought to be a result of 
the elevated levels of Type II cytokines such as IL-4, IL-6, IL-l0, IL-13, PGE2, and 
TGF-(3 in the tumor microenvironment, factors that also may contribute to MDSC 
mobilization (77-83). 
Tregs are a heterogeneous population of either naturally-occurring or 
inducible T cells expressing the transcription factor forkhead box protein 3 (Foxp3) 
that act to suppress immune function and promote tolerance (84-86). Many of these 
cells also express the surface marker ofT cell activation, CD25 (87). Elevated 
numbers ofTregs are found in the tumor microenvironment and periphery in 
multiple cancer types, and they most often correlate with a poor prognosis (88-96). 
Tregs suppress immune function through contact-dependent mechanisms, such as 
through membrane-bound TGF-~, CTLA-4 binding to B7 on target T cells or 
dendritic cells, and expression of F AS ligand or granzyme B, or through contact-
independent mechanisms, such as through secretion of IL-l0, TGF-(3, and IL-4 (87, 
97-101). Depletion of Tregs .. through the use of antibodies targeting CD25 or 
antibodies targeting CTLA-4, has been shown to be beneficial in promoting tumor 
rejection (102-104). 
1.1.3 Inflammation as a Tumor-Promoting Mechanism 
Despite the increasing understanding of the traditional role of the immune 
system during tumor immunoediting, the role of the immune system during the 
development of cancer has proven to be much more complicated than previously 
thought. While directed inflammation in the form of a specific type I immune 
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response may help to eliminate growing and established tumors, unresolved chronic 
inflammation often serves to promote tumorigenesis. Around 20% of cancers are 
associated with chronic infections, such as Helicobacter pylori infection of the 
stomach and hepatitis B or C viral infection of the liver .. while around 30% of 
cancers are attributed to tobacco use and 20% of cancers are attributed to obesity, 
both of which trigger chronic inflammation which has been linked to their tumor-
promoting effects (105-110). The autoimmune conditions ulcerative colitis and 
Crohn's disease greatly increase the risk for intestinal cancers (111). In addition, 
use of anti-inflammatory agents such as COX2 inhibitors has been shown to reduce 
tumor incidence, especially for colon cancer, and possibly even help to reduce tumor 
burden in patients with certain cancers, such as breast and ovarian cancer, when 
used in combination with current treatment modalities (112-114). However, 
chronic inflammatory conditions such as rheumatoid arthritis and psoriasis do not 
increase the risk of cancers of the joints or skin (llS). It is not well understood 
why chronic inflammation in some locations can contribute to cancer risk, while 
chronic inflammation in other locations does not. 
While the relationship between tumor-promoting inflammation and 
antitumor immune responses is not fully elucidated, researchers have been able to 
identify inflammatory immune effectors that may at times promote rather than 
suppress tumorigenesis. As indicated above, a type II response has long been 
associated with a more tumor-promoting than antitumor response, mainly due to 
the downregulation of the type I response. However, type I responses have also 
been shown to contribute to tumor growth. While M1 macrophages produce IL-12, 
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helping to direct a Thl-type response, they are also responsible for the majority of 
the production of tumor-promoting cytokines such as IL-l~, IL-6, and TNFa (116, 
117). IL-l has been shown to be released in response to inhalation of asbestos or 
silica particles or in response to necrotic cell death as seen in a tumor after 
chemotherapeutic treatment or after the tumor's growth outpaces its blood supply, 
and it has been linked to enhanced tumor progression in multiple models (118, 
119). IL-6 and TNFa have been shown to not only enhance tumor progression but 
also directly promote cancer cell growth and survival (117). Even IFN -y producing 
Thl cells and CTLs have been implicated in contributing to tumor promotion, 
progression, and metastasis in certain circumstances (120-122). Th17 cells have 
been linked to an improved prognosis in several cancer types and shown to result in 
a strong antitumor response when adoptively transferred into certain tumor models 
(123-128). Conversely, they have been shown to be associated with a poorer 
prognosis in patients with gastric cancer (129). Also, the main functions of the 
cytokines produced by Th17 cells, IL-17 and IL-23, include intense inflammation, 
angiogenesis, and possibly inhibition of effector CTL function, factors that promote 
tumorigenesis (130-133). 
While it would certainly be preferential for one to be able to place specific 
immune effectors into the categories of IItumor-promoting" or Ilanti-tumor," the role 
of the immune system during the initiation and development of cancer is in fact 
much more complicated. The location, timing, duration, and intensity of the 
immune response are integral to determining the impact of this response. These 
factors and the overall balance of the various inflammatory and anti-inflammatory 
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signals are what determine if conditions are favorable for oncogenesis or tumor 
clearance. The elucidation of each of these individual factors in specific tumor types 
is integral to the development of immunotherapeutic techniques to prevent or 
combat those cancers. 
1.2 Immune Reactivity Potential Toward UNSee 
Head and neck squamous cell carcinomas (HNSCC) are aggressive 
malignancies, and treatment options have traditionally involved surgery or, more 
recently, also radiation plus chemotherapy. Despite advances in treatment options 
and attempts at organ preservation, the success rate of treatment has not improved 
significantly, and current treatments have typically resulted in debilitating effects 
and reduced quality of life (134). An alternative or adjuvant treatment approach 
being tested for various malignancies is immunotherapy, although studies testing 
effectiveness of novel immunotherapeutic approaches for HNSCC are lagging. 
As with other malignancies, the rationale for considering immunotherapy for 
HNSCC is based on the expression of potentially immunogenic antigens that are 
either selectively expressed on malignant versus normal tissues or expressed in 
increased levels, or tumor-associated antigens (TAAs). These antigens include the 
mucin MUC-1, epidermal growth factor receptor (EGFR), the RAGE and GAGE 
families of tumor antigens, NY-ESO-l, and others (135-138). To increase the 
effectiveness of immunotherapeutic strategies, efforts are underway to improve the 
identification of candidate tumor antigens that cause T cell responses. One such 
effort involves the use of a newly developed} automated, two-dimensional 
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chromatography system PF20 that fractionates the proteome of human tumor 
tissues (137). Advances in this area have the potential to reveal more immunogenic 
proteins to target, leading to stronger and more enduring responses to therapy. 
Immunotherapeutic approaches hinge on the ability of the immune system to 
recognize these tumor antigens as foreign and develop a response, humoral and/or 
cellular, against the malignant tissue. Patients with HNSCC have been shown to 
mount antibody responses to antigens that are expressed on the tumor tissue. 
Reactivity includes antibody responses to the mucin MUe-1, with increased serum 
levels ofMUC-1 and antibodies to MUC-1 in patients with more advanced disease 
and nodal involvement (139). Antibodies to p53, which is frequently mutated in 
HNSCC, are also detectable in serum of HNSCC patients and are indicative of nodal 
disease involvement (140). In addition to humoral responses to HNSCC, patients 
can mount cellular immune responses to the tumor. Increased intraepithelial C08+ 
tumor-infiltrating lymphocytes (TILs) in HNSCC metastases, as well as increased 
numbers of CD20+ B cells in involved lymph nodes, are associated with a better 
prognosis (141). Also, both C04+ and CD8+ T cells isolated from patients with 
HNSCC can be activated in response to tumor antigens (137). Antigen processing 
and cross-presentation by dendritic cells to C08+ T cells can stimulate their 
reactivity to tumor antigens. Less well studied has been the potential ofy /0 T cells 
to react to tumor. Recently, a subset ofy /S T cells expressing the NK cell-associated 
molecule CDS6 has been shown to exhibit cytolytic reactivity to HNSCC (142). 
These studies indicate that HNSCC is a good candidate for the development of 
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immunotherapeutic approaches, as HNSCC expresses tumor antigens and the 
immune system has the potential to react against these antigens. 
1.3 HNSee-Induced Defects in Immune Function 
1.3.1 Avoiding Immune Detection and Destruction 
Despite the above-described potential reactivity toward tumor antigens, 
these immune responses have not proven to be sufficient to prevent tumor 
progression. This is likely due to the many mechanisms by which established 
HNSCC tumors achieve immune escape. This includes the development of ways by 
which tumors can avoid detection by the immune system or decrease vulnerability 
to immune effector mechanisms. HNSCC cells have been found to decrease surface 
expression of MHC class I molecules, thereby making them less susceptible to 
detection by tumor specific CTLs (143-145). Further research shows that HNSCC 
cells also downregulate surface expression of costimulatory B7 molecules that are 
necessary for proper T cell signaling (146,147). HNSCC has also been shown to 
avoid immune effector mechanisms by upregulation of surface expression of Fas 
ligand and PD-L1, both of which can induce apoptosis in activated lymphocytes 
(148,149). 
1.3.2 UNSee-Derived Soluble Immune Inhibitory Mediators 
Another way by which HNSCC tumors can achieve immune escape is through 
the induction of profound immune suppression that is characteristic for HNSCC 
patients. In fact .. a prospective study analyzing risk factors for HNSCC patient 
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survival showed that among the top 4 risk factors was the extent of immune 
suppression of the HNSCC patients (150). The mechanisms of immune suppression 
are multifocal. HNSCC produces several immune inhibitory factors including PGEz, 
TGF-(3, VEGF, IL-6, and IL-I0 (151-153), mediators long known to be inhibitory 
toward T-cell functions (154-156). The release ofTGF-[3 and PGEz from HNSCC has 
been shown to correlate with reduced intratumorallevels of T -cells, in particular 
CTLs (157). More recently, dendritic cells of HNSCC patients have been shown to be 
defective in maturation and functionally impaired (158, 159). This impairment is 
attributed in part to the production by HNSCC of VEGF, PGEz and TGF-[3. These 
mediators induce a shift in dendritic cell cytokine production to contribute to a 
more tolerogenic phenotype. They also alter expression of the chemokine receptors 
that are important in allowing dendritic cell migration to tumor-draining lymph 
nodes. In these studies, the dendritic cell dysfunction induced by HNSCC was 
overcome by blocking PGE2 and TGF-f3. Investigation into additional strategies 
aimed at diminishing or avoiding the effects of immune suppressive mediators 
produced by HNSCC may help to enhance the effectiveness of immune stimulatory 
treatment. 
1.3.3 HNSee Induction of Immune Suppressive Cells 
In addition to producing soluble mediators that inhibit immune reactivity of 
HNSCC patients, HNSCC also induces immune inhibitory cells. The levels ofTreg 
cells within HNSCC patients is greater than levels in healthy controls (160, 161). A 
lower ratio of CTLs to Tregs is associated with decreased survival (162). In addition 
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to secreting the immunosuppressive cytokines TGF-~ and IL-l0, Tregs hydrolyze 
ATP to a greater extent and, in turn, cause increased levels of adenosine-mediated 
suppression of effector T cells. However, Bergmann found that Tregs in the 
peripheral blood and tumor were elevated even further in patients with no evident 
disease after oncologic therapy compared to patients with active disease, and 
Badoual found that Treg infiltration into the tumor was actually associated with 
improved locoregional control (163, 164). This association of Treg infiltration with 
an improved prognosis may possibly be attributed to Treg-induced suppression of 
tumor-associated cells producing inflammatory mediators, growth factors, and 
angiogenic factors linked to promotion of advanced HNSCC tumors. This indicates 
that the impact of elevated Treg levels in HNSCC may be more complicated than 
previously believed. 
Another immune suppressive cell that our laboratory has shown to be in 
increased levels in the peripheral blood of HNSCC patients is the immature CD34+ 
progenitor cell. These cells are mobilized from the bone marrow by tumor-derived 
GM-CSF and are chemoattracted into the tumor by VEGF. They mediate their 
immune inhibitory activity by production ofTGF-(3 (55, 76,165,166). Depending on 
the cytokine milieu, the tumor-mobilized CD34+ cells can differentiate into 
granulocytes, monocytes or dendritic cells (55, 165, 167). Studies in animal tumor 
models have shown that these cells can also differentiate into endothelial cells (52). 
In order to alleviate the level of immune suppression in HNSCC patients, our studies 
used the strategy of taking advantage of the immature status of these CD34+ cells 
and driving the differentiation of these inhibitory cells into stimulatory dendritic 
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cells. This was accomplished with treatment of HNSCC patients with the active 
hormone 1,25-dihydroxyvitamin D3 (168, 169). Such a strategy not only resulted in 
a decrease in levels of intratumoral CD34+ suppressor cells and an increase in 
numbers of mature dendritic cells and T cells expressing markers of activation 
within the HNSCC, but it also significantly prolonged the time between surgical 
treatment and cancer recurrence. Others have shown that HNSCC CD34+ progenitor 
cells are induced to produce increased levels of the immune inhibitory mediator, 
IL-6 (170). These CD34+ cells are likely to be an earlier precursor within a spectrum 
of immune inhibitory cells in various stages of differentiation that include MDSCs. 
MDSCs, which are found in a multitude of tumor types including HNSCC, mediate 
their immune suppressive activity mainly through the induction of reactive oxygen 
species production (171). Their suppressive activity can be blocked by inhibiting 
NADPH oxidase. A newly recognized tumor-induced immune suppressive 
population that has been described for HNSCC patients is the immune inhibitory 
endothelial cell (172). The suppressive activity of endothelial cells is induced by 
tumor-derived VEGF. These HNSCC-induced immune inhibitory endothelial cells 
mediate their immune suppressive activity through production of PGE2 which, in 
turn, blocks T-cell proliferation, production of IFN-y, perforin and granzyme B, 
suggesting inhibition of both T-cell helper and cytolytic functions. Blockade of VEGF 
through the use of bevacizumab could potentially prevent the induction of both 
CD34+ progenitor cell and suppressive endothelial cell populations. 
Many studies have focused on determining the mechanisms by which 
established HNSCC escapes an anti-tumor response. However, these studies are 
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complicated by the complex nature of the relationship of the immune system with 
cancer. It is clear that further investigation into the mechanisms by which HNSCC 
manipulates the immune system and strategies to block or reverse the consequent 
immune suppression may greatly assist the efficacy of attempts to stimulate 
immune rejection of HNSCC. Investigation into the origin of these mechanisms by 
examining the immune responses during HNSCC development may help in 
understanding HNSCC-associated immune escape, and such research may uncover 
potential therapeutic avenues by which one may target dysplastic tissue before 
immunosuppression arises. 
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CHAPTER 2: RATIONALE, HYPOTHESIS, AND SPECIFIC AIMS 
2.1 Rationale 
Tumor-induced immunosuppression is utilized by many solid malignancies 
to avoid detection by the immune system as well as to avoid the effects of an anti-
tumor immune response. However, many malignancies arise out of and even 
promote smoldering inflammation concurrently with the induction of 
immunosuppression. The promotion of oncogenesis versus tumor clearance 
depends on a multitude of factors including the mediators involved .. the location of 
the tumor .. and the intensity and timing of the response. Therefore, investigation 
into each of these factors is necessary to determine the appropriate targets for 
immunotherapeutic intervention to combat carcinogenesis. 
HNSCC is a highly aggressive malignancy that has proven difficult to treat, 
with a S-year survival rate of about 500/0, due in part to the many immune evasive 
tactics employed by the tumor (28 .. 150, 163, 164, 173-177). While many of the 
aspects of immune escape utilized by HNSCC have been studied, some of the data 
has been contradictory, such as the clinical implications of the increase in Tregs 
seen in HNSCC (163). Development of oral HNSCC usually begins with the 
appearance of thick adherent plaques, known as leukoplakias and erythroplakias, on 
the floor of mouth, the lip, and the lateral tongue (173). Very little is known about 
the immune response at the premalignant stages. One way to clarify the role of 
immune effectors in established HNSCC is to investigate the immune responses 
elicited during the early stages of dysplasia leading up to HNSCC. In addition, 
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exposure of immune competency at the premalignant stage of HNSCC may provide 
clinicians with an avenue of immunotherapeutic delivery that avoids the 
complications of immunosuppression seen in established HNSCC. 
Novel treatment approaches for HNSCC patients are essential due to the 
minimal level of improvement in patient survival over the last few decades, and 
immunotherapy could be a strong candidate for one such approach. However, some 
approaches to actively stimulate immune reactivity have not lived up to 
expectations in the past, likely due to the multitude of immune inhibitory 
mechanisms that are induced by HNSCC (178, 179). It is possible that initiating 
immunotherapy prior to the development of immune escape may prove more 
successful at preventing the establishment of HNSCC. HNSCC is somewhat unique in 
that it may be diagnosed in its premalignant stages. Also, HNSCC and oral 
premalignant lesions have been shown to share overexpression of certain antigens 
that may be utilized as markers to allow specific recognition of both types of tissues 
by immune effectors (136, 180). Dendritic cell-based vaccines have been used in 
multiple studies as a means to stimulate antitumor immune reactivity through the 
use of primed, activated dendritic cells to activate tumor antigen-specific T cells 
(181-185). The development of premalignant lesion antigen-pulsed dendritic cell 
vaccines, administered at the premalignant stage of HNSCC, may be utilized to 
stimulate protective immunity against further development of premalignant oral 
lesions and progression to HNSCC. 
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2.1.1 Hypothesis 
"We hypothesize that the premalignant stage 0/ HNSCC 
development will be associated with a local increase in inflammatory 
immune effector mechanisms and lack a/immunosuppression while 
established HNSCC will be associated with local and systemic 
immunosuppression. Furthermore~ we hypothesize that administration 
of a premalignant lesion lysate-pulsed dendritic cell vaccine to mice 
bearing premalignant lesions will induce immunity against development 
of premalignant lesions and HNSCC." 
2~1.2 Specific Aims 
This hypothesis will be tested through the following specific aims: 
Aim 1: To investigate the alterations in immune phenotype at the 
premalignant and malignant stages of HNSCC within a 4NQO carcinogen-
induced mouse model and in human patients. 
While HNSCC is associated with widespread immune manipulation, it 
is likely that this phenomenon has not yet developed or has developed to a 
lesser degree at the premalignant stage. Aim 1 analyzes the immune 
responses at the local and systemic levels in mice treated with the carcinogen 
4NQO until the development of premalignant lesions or HNSCC and humans 
with premalignant lesions or HNSCC. 
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Aim 2: To use premalignant lesion-pulsed dendritic cells in vivo to skew 
the immune phenotype within mice bearing premalignant lesions 
towards imm unity against further development of premalignant oral 
lesions and progression to HNSCC. 
Initiation of immunotherapy at the premalignant stage of HNSCC may 
have the increased success because of the avoidance of the widespread 
immunosuppression seen in HNSCC. As both premalignant lesions and 
HNSCC share overexpression of common tumor antigens, dendritic cell 
vaccination using premalignant lesion lysate as an antigen source may be 
able to promote an anti-tumor response. Aim 2 investigates if premalignant 
lesion lysate-pulsed dendritic cell vaccination of mice bearing premalignant 
lesions can stimulate protective immunity against the further development of 
premalignant lesions and progression to HNSCC. 
2.2 Significance 
Many studies have explored the local and systemic immune evasive factors 
employed by established HNSCC. However, it is still unclear what the roles of each 
cell type are in the HNSCC microenvironment. In addition, this immunosuppression 
has impeded attempts at the immunotherapeutic stimulation of an anti-tumor 
response. A goal of this study is to further investigate the immune alterations in the 
setting of HNSCC as well as to, for the first time, investigate the immune alterations 
during the development of HNSCC. Not only will this help to understand the roles of 
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the immune system in HNSCC, it will also help in identifying specific targets and 
possible avenues for the development of immunotherapeutic techniques to either 
prevent or treat HNSCC. 
This study also aims to further explore the feasibility of using premalignant 
lesion-pulsed dendritic cells as a preventative treatment for HNSCC, a disease that 
presently has few effective treatments and a high mortality rate. Optimally, the 
initiation of this treatment at the premalignant stage will allow for the development 
of an effective anti-tumor response without the obstacle of the extensive 
immunosuppression seen with HNSCC. This will ideally lead to the identification of 
individual antigens in these tissue types responsible for eliciting immunity, allowing 
for the development of an antigen-specific vaccine that could be applied to multiple 
patients. The long-term goal is to use vaccination to prevent recurrence in patients 
who have developed oral premalignant lesions and had them surgically removed, as 
these patients would still have a high risk of developing more premalignant lesions 
and HNSCC if left untreated. 
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CHAPTER 3: IMMUNE RESPONSE TO HNSCC DEVELOPMENT 
Aim 1: To investigate the alterations in immune phenotype at the premalignant 
and malignant stages of HNSCC within a 4NQO carcinogen-induced mouse model 
and in human patients. 
3.1 Introduction 
Head and neck squamous cell carcinoma (HNSCC) is an aggressive 
malignancy that has proven quite difficult to treat. Despite advances in care over 
the past 30 years, the five-year survival rate remains around 50% (173), with a five-
year survival rate of 28% for patients with advanced HNSCC (186). In addition to 
the high mortality rate, surgical treatment of advanced HNSCC is associated with 
significant morbidity due to the major disfiguring consequences and functional 
defects that can result (173, 186). However, this malignancy is somewhat unique in 
that, with proper care and attention, it can be diagnosed in its premalignant stages 
as white or red patches on the oral mucosa referred to as leukoplakias or 
erythroplakias. If diagnosed at this stage, prognosis is conSiderably improved .. 
though another hallmark of oral premalignancy and HNSCC is a high likelihood of 
recurrence (173). Therefore, our focus is shifting towards identifying this disease in 
its premalignant stages and ultimately developing treatment strategies to halt 
progression towards established HNSCC. 
Multiple studies have indicated that HNSCC is associated with immune 
suppression and manipulation, factors that may contribute to the tenacity of this 
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disease. Patients with acquired or iatrogenic immunodeficiencies have an increased 
incidence of HNSCC (174, 175). HNSCC patients exhibit increased levels of 
regulatory T cells (Tregs) (163, 164, 176) and C034+ progenitor cells (177), both 
suppressive cell populations. Studies have identified skewing of the ThljTh2 
balance within HNSCC patients to a Th2 dominant phenotype with decreased Thl 
activity (28, 176), indicating tumor-induced manipulation of the environment to 
prevent an effective anti-tumor response. However, while an increase in the CD34+ 
population is associated with a poor patient outcome (177l Treg infiltration into 
the tumor was shown to be associated with improved locoregional control (164). In 
addition, recent studies revealed that peripheral blood mononuclear cell (PBMC) 
and tumor infiltrating Tregs are elevated even further in patients with no evident 
disease after oncologic therapy compared to those with active disease (163). 
Further complicating the matter is the fact that few to none of these studies 
stratified by HPV status. HPV-positive HNSCC, representing a minority of cases, has 
a more favorable prognosis compared to classic HPV-negative HNSCC, a 
phenomenon which appears to be related to the differing immune response to 
HPV( +) vs. HPV(-) disease (187). In fact, one study showing that CD3high tumors 
have decreased metastasis rates than CD3low tumors found that their results only 
held for HPV( +) tumors (188), indicating that conclusions drawn from previous 
studies may be influenced by HPV status of study participants. 
In addition to gaps associated with HNSCC etiology, little to no research thus 
far has focused on investigating the immune status at the premalignant stage of 
HNSCC carcinogenesis. One study showed that expression of Fas, a death receptor 
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that renders a cell susceptible to immune-induced apoptosis through binding with 
its ligand (FasL), and expression of FasL itself were increased significantly in human 
oral premalignant tissue compared to normal control. While Fas levels in malignant 
tissue decreased to below control levels, levels of FasL continued to rise in 
malignant tissue compared to premalignant tissue, a phenomenon associated with 
immune escape as tumor-associated FasL can trigger apoptosis of infiltrating 
lymphocytes (189, 190). Though these results indicate that a significant immune 
response may take place in dysplastic oral tissue, no further studies into this topic 
have been carried out. Consequently, research into the immune response during 
and after the development of HPV-unrelated HNSCC is necessary in order to gain 
greater insight into possible future immunotherapeutic techniques that may be 
utilized to prevent or reverse HNSCC progression. 
The present study investigates the proportions and total numbers of specific 
populations of immune cell types within cervical lymph nodes of control mice and 
mice bearing oral premalignant lesions or HNSCC, using a model of 4-nitroquinoline 
i-oxide (4NQO)-induced carcinogenesis (191). While there are multiple models 
that may be used to study HNSCC, such as the HPV( +) cancer model (192) and the 
orthotopic SCC VII syngeneic tumor system (193), we chose to use this model of 
4NQO-induced carcinogenesiS because it allowed the study of HPV( -) disease versus 
HPV( +) disease, which has a significantly better prognosis (194), and it permitted 
the analysis of the immune response during the gradual progression to HNSCC 
rather than the immune response to injection of malignant cells. In addition, 4NQO 
mimics the carcinogenic effects of tobacco, the highest risk factor for HNSCC (173, 
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191). As tongue epithelium was determined to contain very low numbers ofT cells 
and immune responses are most often orchestrated in draining lymph nodes, 
analysis focused on the cervical lymph nodes. Lymph nodes were analyzed to 
evaluate immune cell makeup of response .. and tongue epithelium was lysed to 
determine presence of various cytokines. Due to trends reported in the literature .. it 
was hypothesized that development of HNSCC would be associated with a gradual 
increase in immunosuppressive populations such as regulatory T cells and Th2 cells 
and a decrease in Thl and Tel cell populations. While the current study verifies 
that HNSCC-bearing mice exhibit an increase in Treg populations, it is also revealed 
that the presence of HNSCC is associated with an increase in activated conventional 
CD4+ and C08+ T cell populations, including an increase in Thl and Tcl cells that is 
not accompanied by an increase in Th2 cells. In addition, it was determined that the 
premalignant stage is associated with an increase in the percentage of activated and 
memory conventional T cells, as well as an increase in the percentage ofThl and 
Tel cells compared to control and an increase in the percentage ofTh17 cells 
compared to control and HNSCC-bearing mice. 
Human samples were also tested for cytokine levels as a preliminary 
indicator of immune status. Normal/adjacent tongue tissue .. premalignant tissue, 
and tumor tissue were obtained from human patients. Peripheral blood was also 
collected from unaffected individuals, premalignant lesion-bearing individuals, and 
HNSCC patients. Cytokine bead array analysis of tissue lysate and peripheral blood 
revealed a similar trend as what was detected in mice: while the expected local 
increase in IL-l0 in HNSCC tissue was observed, there was also a local increase in 
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IFN-y in HNSCC tissue compared to normal/adjacent tissue. In addition .. analysis 
showed an impressive increase in the Thl cytokines IFN-y and IL-2 and the Th17 
cytokine IL-17 A in human premalignant tissue compared to both normal/adjacent 
and HNSCC tissue. 
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3.2 Materials and Methods 
Oral HNSCC carCinogenesis 
Five mg/ml 4NQO was administered in propylene glycol stock in the drinking 
water (diluted to SO llg/ml) of 2 month old (at start) female CS7BL/6 mice (Charles 
Rivers Laboratory, Wilmington, MA) until development of premalignant oral lesions 
(6-8 weeks) or HNSCC (12-16 weeks). Control mice received propylene glycol 
diluent. To monitor development of premalignant oral lesions and HNSCC, oral 
cavities of 4NQO-treated mice were endoscoped weekly using a Stryker 1.9mm x 
30° scope and a Stryker 1088 HD camera. Mice were sedated with inhaled isoflurane 
(Piramal Healthcare, Mumbai, India) during the procedure. 
Cervical lymph node processing 
Cervical lymph nodes were harvested from C57BL/6 mice and homogenized 
via a Stomacher 80 homogenizer (Seward, West Sussex, UK) set on high for 90 sec. 
Cells were passed through a 40-llm cell strainer (BD Falcon, San Jose .. CA) and rinsed 
with Hank's Buffered Saline Solution (HBSS, Invitrogen, Carlsbad, CA) to remove 
debris. Cells number was determined by counting cells excluding trypan blue using 
a hemocytometer. 
Human samples 
Recruitment of patients into this study was approved by the Institutional 
Review Board of record. Peripheral blood samples and tissue samples were 
collected from patients bearing premalignant lesions or HNSCC, and surgically 
Chapter 3 28 Immune Response to HNSCC Development 
Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination 
excised HNSCC and premalignant tissues were cryopreserved at -800 C until used for 
cytokine analyses. HNSCC tissues from untreated patients were also obtained from 
the Medical University of South Carolina Tissue Biorepository. Normal, non-
carcinogenic oral tissue was procured from the adjacent areas bordering oral cancer 
tissue .. and these tissues were deemed pathologically normal with no microscopic 
evidence of invasive carcinogenic disease. 
Flow cytometric analysis o/surface markers and Foxp3 expression 
All reagents in this section were from BO Biosciences (San Jose .. CA) unless 
otherwise specified. In order to detect levels of C08 and CD4 positive cells in 
relation to Foxp3 and CDllb+Gr-l + MOSes, ex vivo cervical lymph node cells in 
single-cell suspension were washed once in Stain Buffer and resuspended at 1x107 
cells/ml. Nonspecific staining of a total of lxl0 6 cells was blocked with FBS and 
anti-CD16/32 monoclonal antibody prior to cell surface staining with the following 
antibodies: PerCP-CyS.S CD4 .. FITC CD8a, PE Gr-1, PE CD2S, PE PD-1, APC CD11b, 
APC CD44, APe CD69, and APC KLRGl (eBioscience, San Diego, CA). Intracellular 
staining for PE-Cy7 Foxp3 (eBioscience, San Diego, CA) was performed after fixation 
with Foxp3 Fixation Buffer and permeabilization with Foxp3 Permeabilization 
Buffer. Extent and frequency of positively stained cells was visualized using flow 
cytometry (FACSCanto .. San Jose, CA). 
Flow cytometric analYSis of cytokine expression 
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All reagents in this section were from BD Biosciences (San Jose, CA) unless 
otherwise specified. In order to detect intracell ular cytokines, single-cell 
suspensions of cervical lymph node cells were restimulated for 4 hours at 37°C with 
50 ng/ml phorbol 12-myristate 12-acetate (PMA), 1 Ilg/ml ionomycin, and 
brefelden A solution. Nonspecific staining of total of lxl06 cells was blocked with 
FBS and anti-CD16/32 monoclonal antibody prior to cell surface staining with the 
following antibodies: PerCP-Cy5.S CD4 and PE-Cy7 CDBa. Intracellular staining for 
PE IL-17 A, FITC IFN-y, APe IL-4, APC IL-I0 and Alexa Fluor 488 IL-13 (eBioscience, 
San Diego, CA) was performed after fixation/permeabilization with 
Cytofix/Cytoperm. Extent and frequency of positively stained cells was visualized 
using flow cytometry (FACSCanto, San Jose, CA). 
Cytokine bead array 
All reagents in this section were from BD Biosciences (San Jose, CA) unless 
otherwise specified. In order to detect cytokines released into supernatant, single-
cell suspensions of cervical lymph node cells were restimulated for 4 hours at 37°C 
with SO ng/ml PMA and 1 I-lg/ml ionomycin without addition of brefeldin A. In 
order to detect cytokine levels in tongue tissue, mouse tongue epithelium was 
obtained after incubation of tongue fragments with Dispase II (Roche, Florence, SC). 
Both mouse and human tissue was lysed through sonication, protein concentration 
was determined by BCA protein assay (Pierce, Rockford, IL) per manufacturer's 
instructions, and final cytokine levels in tissue were normalized to pg/l00Jlg of 
protein. Levels of IFN-y, IL-2, IL-17 A, IL-4, and IL-I0 in cell supernatant or tongue 
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epithelium lysate were determined using a mouse cytometric bead array 
ThljTh2jTh 17 cytokine kit .. while levels of RANTES, MIP-1u, MIP-1f3, and IL-13 in 
cell supernatant or mouse tongue epithelium lysate were determined using 
cytometric bead array flex sets for the individual cytokines according to the 
manufacturer's instructions. Relative amounts of each cytokine were analyzed 
using FCAP Array software (San Jose, CA). 
T cell purification and functional assays 
CD4+CD2S- conventional T cells and CD4+CD2S+ regulatory T cells were 
purified from mouse cervical lymph nodes using Dynabeads FlowComp Mouse 
CD4+CD25+ Treg Cell Isolation Kit (Invitrogen .. Carlsbad, CA). To measure T cell 
proliferative response, CD4+CD25- Teonv cells from control, premalignant lesion-
bearing, and HNSCC-bearing mouse lymph nodes were labeled with CFSE using the 
CellTrace CFSE Cell Proliferation Kit (Invitrogen, Carlsbad, CA) and cultured for 3 
days in the presence of Dynabeads Mouse T -Activatory anti-CD3janti-CD28 beads 
(Invitrogen .. Carlsbad, CA). To measure T cell suppression .. CFSE-Iabeled control 
CD4+CD25- Tconv cells were incubated for 3 days with control, premalignant lesion-
bearing mouse, and HNSCC-bearing mouse CD4+CD25+ Treg cells at a 1:1 ratio with 
anti-CD3janti-CD28 beads. Cell proliferation was measured by percentage of cells 
with diluted CFSE. 
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Statistical analysis 
Data were reported using the mean as a measure of central tendency ± 
standard error of the mean. To compare one variable condition between groups, the 
2-tailed Student's t-test or Mann-Whitney U test was used. Significance was 
reported in the 950/0 confidence interval. 
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3.3 Results 
Increase in absolute number of cervical lymph node cells in mice bearing HNSCC 
compared to control mice and mice bearing premalignant oral lesions 
Draining regional lymph nodes may become hyperplastic during the 
development and progression of malignancy due to reactive lymphadenopathy, 
metastasis, or both (195). To determine if draining lymph nodes undergo 
hyperplasia during the premalignant stage or malignant stage of HNSCC 
development, cervical lymph nodes from control mice, premalignant oral lesion-
bearing mice, and HNSCC-bearing mice were processed to single cell suspension, 
and the number of try pan-blue excluding cells were counted. While mice bearing 
premalignant oral lesions exhibit equal numbers of cervical lymph node cells as 
control mice (4.94 xl06 ± 6.2Sx10s vs. 5.31x106 ± 7.29xl0s .. p = 0.362) .. mice bearing 
HNSCC exhibit a marked increase in number of cervical lymph node cells to more 
than double the number found in control mice (1.17xl07 ± 2.63x106 vs. 5.31xl06 ± 
7.29xl0s, p = 0.006). This indicates that draining lymph node hyperplasia occurs to 
a great extent after establishment of HNSCC but not during premalignant stages of 
HNSCC development. 
Increase in total number of conventional and regulatory lymphocytes in cervical lymph 
nodes o/mice bearing HNSCC compared to control mice and mice bearing 
premalignant oral lesions 
Many solid carcinomas, including HNSCC .. have classically been associated 
with immunosuppression involving decreased conventional (Foxp3-) T cells and 
Chapter 3 33 Immune Response to HNSCC Development 
Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination 
increased regulatory (Foxp3+) T cells and myeloid derived suppressor cells (MDSC), 
contributing to immune escape (163, 164, 176). The upregulation of a conventional 
T cell response is typically a goal of antitumor immunotherapy. While CD8+ 
cytotoxic T cells have long been considered to be the most beneficial in actively 
combatting tumorigenesis through cytotoxic activity, recently CD4+ conventional T 
cells have recently been shown to exhibit cytolytic activity that is beneficial in 
eradicating established tumors (196, 197). To determine the relative composition 
of CD4+ and CD8+ conventional T cells and regulatory T cells, as well as MDSCs, in 
cervical lymph nodes of control, premalignant lesion-bearing mice} and HNSCC-
bearing mice, lymph node cells were stained for surface expression of CD4} CD8, 
CDi1b, and Gr-l and intracellular expression of the regulatory T cell marker Foxp3. 
Proportions of populations expressing each marker were determined through flow 
cytometric analysis of stained cells (Fig 3.1a and b J. while total numbers of 
populations expressing each marker (Fig 3.1c) were determined by multiplying the 
percent positive by the number of lymph node cells for each individual mouse. 
While no differences in CD11b+Gr-1 + MDSCs were observed among the three groups 
(data not shown), HNSCC-bearing mouse lymph nodes consist of a greater total 
number of conventional helper (CD4+Foxp3-) and cytotoxic (CD8+Foxp3-) T cells and 
CD8+Foxp3+ regulatory T cells as well as a greater proportion and total number of 
CD4+Foxp3+ regulatory T cells compared to both control and premalignant lesion-
bearing mouse lymph nodes (Fig 3.1b and c). This indicates that establishment of 
HNSCC is associated not only with increased regulatory T cell levels but also with 
increased numbers of conventional CD4+ and CD8+ T cells. 
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Ratios of conventional to regulatory T cells were determined by dividing 
number of CD4+Foxp3- or CD8+Foxp3- conventional T cells by number of 
CD4+Foxp3+ or CD8+Foxp3+ regulatory T cells for each individual mouse. As shown 
in Fig ld} while there is no significant difference between CD8+ 
conventional:regulatory T cell ratio between the three groups, both premalignant 
lesion-bearing mice and HNSCC-bearing mice have a CD4+ conventional:regulatory T 
cell ratio that is significantly lower than control. This suggests that while lymph 
node cells from HNSCC-bearing mice exhibit large changes in numbers of both 
conventional and regulatory CD4+ T cells .. the relative degree of these changes 
results in a relative proportion of these cells which is similar to the proportion 
resulting from the minor decrease in CD4+ conventional T cells and minor increase 
in CD4+ regulatory T cells seen in lymph nodes of premalignant lesion-bearing mice. 
Decrease in proliferation of conventional T cells from HNSCC-bearing mouse lymph 
nodes in response to stimulation compared to control. 
Due to the unexpected increase in total number of conventional T cells in 
mice bearing HNSCC compared to control mice .. the proliferative capacity of these 
cells in response to stimulation was evaluated. Conventional CD4+CD2S- T cells 
were isolated from control, premalignant lesion-bearing} and HNSCC-bearing mouse 
lymph nodes by magnetic isolation, stained with CFSE .. and cultured for 3 days with 
or without anti-CD3 and anti-CD28. Conventional CD4 cells from HNSCC bearing 
mice had a significantly decreased percentage of proliferation compared to control 
mice (Figure 3.1e). This was supported by cytokine analysis of cell supernatant 
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which revealed a decrease in IL-2 released into the supernatant of HNSCC-bearing 
mouse conventional CD4 cells compared to control conventional CD4 cells (Figure 
3.1f). The levels of CD4+CD25- conventional T cell proliferation and IL-2 release at 
the premalignant stage fell in the middle of levels for control cells and HNSCC-
bearing mouse cells. 
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Fig 3.1 Established HNSee is associated with an increase in numbers of 
regulatory and conventional T cells in cervical lymph nodes of affected mice 
Representative results (a) and graphical representation (b) of flow cytometric 
staining of cervical lymph node cells from control, premalignant lesion-bearing 
(PM), and HNSCC-bearing mice (HNSCC) with at least 3 mice per group. *, p < O.OS. 
Total numbers of populations (c) were determined by multiplying the percent 
positive by the number of cervical lymph node cells for each individual mouse. *, p 
< O.OS. **, P < 0.01. ***, P < 0.001. The CD4+ conventional T cell to regulatory T cell 
ratio of both premalignant lesion-bearing and HNSCC-bearing mice is significantly 
decreased compared to control Cd). *j p < 0.05. Representative results and 
graphical representation (e) of flow cytometric analysis of CFSE-stained CD4+CD2s-
conventional T cells from control, premalignant lesion-bearing mouse, and HNSCC-
bearing mouse lymph nodes (at least 3 mice per group) after three days culture 
with no stimulation (unstim) or stimulation with anti-CD3/anti-CD28 beads (stirn). 
Cell proliferation was measured by percentage of cells with diluted CFSE. *, P < 
0.05. Cytometric bead array analysis (t) of CD4+CD2s- conventional T cell 
supernatant. *, p < 0.05. Representative results and graphical representation (g) of 
flow cytometric analysis of CFSE-stained control CD4+CD2S- conventional T cells 
after coincubation at a 1:1 ratio for three days with control mouse, premalignant 
lesion-bearing mouse, or HNSCC-bearing mouse (at least 3 mice per group) 
CD4+CD2S+ regulatory T cells in the presence of anti-CD3/anti-CD28 beads. *} p < 
0.05. 
Decrease in suppressive capacity of regula tory T cells from HNSCC-bearing mouse 
lymph nodes compared to control regulatory T cells. 
As it was counterintuitive to observe a simultaneous increase in both 
conventional and regulatory T cells in the HNSCC-bearing mouse lymph nodes} the 
suppressive function of the regulatory T cells was investigated. Magnetically 
isolated control, premalignant-bearing, and HNSCC-bearing mouse lymph node 
CD4+CD2s+ regulatory T cells were co-incubated with CFSE-stained control 
CD4+CD2s- conventional T cells at a 1:1 ratio for 3 days in the presence of anti-CD3 
and anti-CD28. As seen in Figure 3.1g, HNSCC-bearing mouse regulatory T cells 
were found to be significantly less suppressive of control conventional T cells 
compared to control mouse regulatory T cells, and the premalignant lesion-bearing 
mouse regulatory T cells suppressed control Tconv cells at a level that was 
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intermediate between control and HNSCC-bearing mouse Tregs. This indicates that 
while Tregs increase in number during HNSCC development, these cells may also 
lose their ability to inhibit conventional T cell proliferation. 
Increased percentage of lymphocytes expressing markers for activation~ memory~ and 
exhaustion in cervical lymph nodes o/mice bearing premalignant oral lesions 
compared to both control mice and mice bearing HNSCC 
An optimal antitumor response depends on the activation, expansion and 
survival of memory T cells. Suboptimal immune responses involve increased 
numbers of T cells expressing markers of exhaustion (198, 199). To determine the 
make-up of these phenotypic subsets between cervical lymph node cells from 
control, premalignant lesion-bearing mice and HNSCC-bearing mice, CD4+Foxp3-
helper T cells and CD8+Foxp3- cytotoxic T cells were analyzed for expression of the 
activation markers C025 and CD69, the marker of antigen experience, CD44, and the 
exhaustion markers PD-l and KLRG1. As shown in Fig 3.2a and b, lymph node cells 
from premalignant lesion-bearing mice exhibit a nearly 4-fold increase in percent of 
CD25+ helper T cells compared to control and a nearly doubled percentage of C025+ 
helper T cells compared to HNSCC-bearing mice. HNSCC-bearing mice show a 
significant but minor increase in percent of CD25+ cytotoxic T cells compared to 
control. When factoring in total number of positive cells, while premalignant lesion-
bearing mice maintain an increased number of CD2S+ helper T cells compared to 
control, HNSCC-bearing mice have an increased number of CD25+ and CD69+ helper 
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and cytotoxic T cells compared to both control and premalignant lesion-bearing 
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Fig 3.2 Premalignant lesion-bearing mouse and UNSee-bearing mouse 
cervical lymph nodes exhibit an increase in activated conventional T cells 
compared to control mouse cervical lymph nodes 
Representative results (a) and graphical representation (b) of flow cytometric 
analysis of cervical lymph node cells from control, premalignant lesion-bearing 
(PM), and HNSCC-bearing mice (HNSCC) with at least 3 mice per group. *, p < O.OS. 
***, P < 0.001. Total numbers of populations (c) were determined by multiplying 
percent positive by number of cervical lymph node cells for each individual mouse. 
*, p < O.OS. **, P < 0.01. ***, P < 0.001. 
Increased expression of the surface marker CD44 is used to distinguish T 
cells with antigen experience from those that are naIve (200, 201). Analysis of 
expression of the T cell memory marker C044 reveals that lymph nodes of mice 
bearing premalignant oral lesions consist of a greater percentage of C044high helper 
T cells compared to control and a greater percentage of C044high cytotoxic T cells 
compared to both control and HNSCC-bearing mice (Fig 3.3a and b). However, 
HNSCC-bearing mouse lymph nodes have a greater total number of C044high helper 
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T cells compared to both control and premalignant lesion-bearing mice and a 
greater number of CD44high cytotoxic T cells compared to controls, again due to an 
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Fig 3.3 Premalignant lesion-bearing mouse cervical lymph nodes consist of a 
greater percentage of CD44high memory conventional T cells compared to 
control and UNSCC-bearing mice 
Representative results (a) and graphical represen tation (b) of flow cytometric 
analysis of cervical lymph node cells from control, premalignant lesion-bearing 
(PM), and HNSCC-bearing mice (HNSCC) with at least 3 mice per group. *, p < O.OS. 
**, P < 0.01. Total numbers of populations (c) were determined by multiplying 
percent positive by number of cervical lymph node cells for each individual mouse. 
**, p < 0.01. ***, P < 0.001. 
Expression of the markers PD-l or KLRG 1 indicates that a T cell has been 
activated yet is at the point in its lifespan where, upon further stimulation, it will 
undergo programmed cell death rather than perform effector functions (199, 202). 
As such, these markers are often used to indicate T cell exhaustion. Analysis of 
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expression of PD-l and KLRGl on conventional T cells in the lymph nodes of control, 
premalignant lesion-bearing and HNSCC-bearing mice revealed that premalignant 
lesion-bearing mice have a significant but minor increase in percent of KLRGl + 
helper T cells compared to both control and HNSCC-bearing mice, while HNSCC-
bearing mice have a decreased percentage of KLRGI + helper T cells compared to 
control as well (Fig 3.4a and b). When comparing total numbers of positive cells 
(Fig 3.4c), HNSCC-bearing mouse lymph nodes consist of a greater number of PD-l + 
helper and cytotoxic T cells compared to both control and premalignant lesion-
bearing mice. Taken together, this data indicates that the premalignant stage of 
HNSCC development is associated with an increase in activated, memory 
conventional T cells, some of which become exhausted, compared to control and 
HNSCC-bearing mice. When it comes to total number of positive cells, however, the 
prominent increase in cervical lymph node cellularity in mice with established 
HNSCC makes it appear as though there is an increase in activated, memory and 
exhausted T cells at this stage compared to the premalignant stage and control. 
Cervical lymph nodes o/premalignant oral lesion-bearing and HNSCC-bearing mice 
exhibit an increase in percent and total number of Thl, Tcl and Th17 cells as well as 
an increase in secretion ofThl, Tel and Th17-related cytokines and chemokines 
compared to control 
To investigate the degree of upregulation or downregulation of different 
subtypes of cytokine-secreting effector T cells during the progression to HNSCC, 
cervical lymph node cells from control mice .. premalignant lesion-bearing mice, and 
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Fig 3.4 Premalignant lesion-bearing mouse cervical lymph nodes contain an 
increased percentage of KLRG 1 + helper T cells, while UNSee-bearing mouse 
cervical lymph nodes contain a greater total number of PD-l + conventional T 
cells 
Representative results (a) and graphical representation (b) of flow cytometric 
analysis of cervical lymph node cells from control, premalignant lesion-bearing 
(PM), and HNSCC-bearing mice (HNSCC) with at least 3 mice per group. *, p < O.OS. 
**, P < 0.01. Total numbers of populations (c) were determined by multiplying 
percent positive by number of cervical lymph node cells for each individual 
mouse. *, p < O.OS. **, P < 0.01. 
HNSCC-bearing mice were stimulated for four hours with PMA and Ionomycin with 
or without brefeldin A. Cells incubated with brefeldin A were stained for CD4, CDS, 
and the cytokines IFN-y, IL-17A, IL-13, IL-4, and IL-I0 and analyzed by flow 
cytometry. Supernatants of cells incubated without brefeldin A and lysates of 
tongue epithelium from each mouse group were analyzed by cytometric bead array 
for presence of the Th 1 fTcl-related cytokines IFN -y and IL- 2 and chemokines 
NTES, MIPl-u and MIP-l~, the Thl7-related cytokine IL-17A, and the Th2-related 
cytokines IL-13, IL-6, IL-4, and IL-I0. 
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An ideal antitumor immune response is often described as involving an 
increased in Thl and Tel type immunity, and the upregulation of this population is 
often considered a target goal of cancer immunotherapy (203). Many solid tumors, 
including HNSCC, have been linked to a decrease in Thl immunity in past studies 
(28 .. 176). As shown in Fig 3.5a and b .. premalignant lesion-bearing mice exhibit an 
increase in percentage of lymph node cells staining double positive for CD4 and IFN-
y (Thl cells) and lymph node cells staining double positive for CDB and IFN-y (Tcl 
cells) compared to controls. HNSCC-bearing mice have an even higher percentage of 
Thl cells compared to both control and premalignant-lesion bearing mice and an 
increased percentage of Tel cells compared to control alone. After factoring in total 
number of lymph node cells (Fig 3.5c), premalignant lesion-bearing mice have a 
greater number ofTcl cells compared to control} while HNSCC-bearing mice have a 
greater number of both Thl and Tcl cells compared to control. Levels of secreted 
cytokines and chemokines help confirm these results, as supernatants of cells from 
both premalignant lesion-bearing and HNSCC-bearing mice contain increased IFN-y .. 
IL-2, RANTES, MIP-la and MIP-1P compared to control mice (Fig 3.Sd). While the 
level of IL-2 in tongue epithelium lysate was lower in HNSCC-bearing mice 
compared to control .. the levels on IFN-y} RANTES, MIP-1a and MIP-lf3 were found 
to be higher in premalignant epithelium lysate and HNSCC epithelium lysate 
compared to control (Figure 3.Se). This data suggests that Thl and Tel immunity is 
stimulated early in development of HNSCC .. during the premalignant stages, and is 
sustained even after HNSCC is established, contrary to what some previous studies 
have indicated (28, 176). 
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Fig 3.5 ThljTcl cells and related cytokines are increased in cervical lymph 
nodes of premalignant lesion-bearing and HNSee-bearing mice 
Representative results (a) and graphical representation (b) of flow cytometric 
analysis of control, premalignant lesion-bearing mouse, and HNSCC-bearing mouse 
cervical lymph node cells after stimulation for four hours with phorbol 12-myristate 
13-acetate (PMA) and ionomycin in the presence of brefeldin A, with at least 9 mice 
per group. *, p < 0.05. **, p < 0.01. Total numbers of populations (c) were determined 
by multiplying percent positive by number of cervical lymph node cells for each 
individual mouse. *, p < 0.05. Cytometric bead array analysis (d) of control, 
premalignant lesion-bearing mouse, and HNSCC-bearing mouse cervical lymph node 
cells after stimulation for four hours with PMA and ionomycin, with at least 9 mice 
per group. *, p < 0.05. **, p < 0.01. Cytometric bead array analysis (e) of control, 
premalignant lesion-bearing mouse, and HNSCC-bearing mouse tongue epithelium 
lysate, with normalization to 100 \lg of protein (as determined by BCA protein assay), 
with at least 10 mice per group. *, p < 0.05. 
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The role of Thl7 cells in tumor immunology is less well defined than that of 
Thl and Tcl cells. While populations ofTh17 cells have been shown to be expanded 
in multiple cancer types, including HNSCC, the benefit and/or detriment of these 
cells remains under debate (204, 20S). Both premalignant lesion-bearing and 
HNSCC-bearing mouse lymph nodes contain a greater percentage (Fig 3.6a and b) 
and number (Fig 3.6c) ofThl7 (CD4+IL-17 A+) cells compared to control mouse 
lymph nodes, while premalignant lesion-bearing mouse lymph nodes contain a 
greater percentage ofTh17 cells than HNSCC-bearing mouse cervical lymph nodes 
(Fig 3.6a and b). This is supported by the cytometric bead array analysis showing a 
greater amount of IL-l7 A released into the supernatant of premalignant lesion-
bearing mouse lymph node cells compared to control (Fig 3.6d). Levels of IL-17 A in 
tongue epithelium lysate were too low to be detected by cytometric bead analysis. 
This data indicates that development of premalignant lesions is associated with an 
inflammatory immune response consisting ofTh1, Tel and Thl7 cells, and that 
while the Thl response is sustained throughout HNSCC establishment and 
progression, the Th 17 response wanes. 
Among the many immune evasive mechanisms often employed by solid 
malignancies, the skewing of a Th1-driven cell-mediated response into a less 
effective Th2-driven humoral response has been described as occurring in the 
setting of HNSCC (28, 176). The only significant difference among Th2 cytokines 
identified by flow cytometric analysis of lymph node cells is a minor decrease in 
percent of CD4+IL-13+ cells in lymph nodes of HNSCC-bearing mice compared to 
premalignant lesion-bearing mice (Fig 3.7a and b). Of the Th2 cytokines measured 
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Fig 3.6 Th17 cells are increased in cervical lymph nodes of premalignant 
lesion-bearing and UNSee-bearing mice 
Representative results (a) and graphical representation (b) of flow cytometric 
analysis of control, premalignant lesion-bearing mouse, and HNSCC-bearing mouse 
cervical lymph node cells after stimulation for four hours with phorbol 12-myristate 
13-acetate (PMA) and ionomycin in the presence of brefeldin A, with at least 9 mice 
per group. *, p < O.OS. ***, P < 0.001. Total numbers of populations (c) were 
determined by multiplying percent positive by number of cervical lymph node cells 
for each individual mouse. *, p < O.OS. **, P < 0.01. Cytometric bead array analysis (d) 
of control, premalignant lesion-bearing mouse, and HNSCC-bearing mouse cervical 
lymph node cells after stimulation for four hours with PMA and ionomycin, with at 
least 9 mice per group. **, p < 0.01. 
in supernatants, only a small decrease in level of IL-4 released from HNSCC-bearing 
mouse lymph node cells compared to premalignant lesion-bearing mouse lymph 
node cells was detected (Fig 3.7d). The measurement ofTh2 cytokines in tongue 
epithelium lysate revealed no significant differences between the three mouse 
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groups (data not shown). This indicates that HNSCC development is not strongly 
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Fig 3.7 No major changes in levels ofTh2 cells or cytokines between cervical 
lymph nodes of control, premalignant lesion-bearing and HNSee-bearing 
mice. 
Representative results (a) and graphical representation (b) of flow cytometric 
analysis of control, premalignant lesion-bearing mouse, and HNSCC-bearing mouse 
cervical lymph node cells after stimulation for four hours with phorbol 12-myristate 
13-acetate (PMA) and ionomycin in the presence of brefeldin A, with at least 7 mice 
per group. *, p < O.OS. Total numbers (c) of populations were determined by 
multiplying percent positive by number of cervical lymph node cells for each 
individual mouse. Cytometric bead array analysis (d) of control, premalignant 
lesion-bearing mouse, and HNSCC-bearing mouse cervical lymph node cells after 
stimulation for four hours with PMA and ionomycin, with at least 9 mice per group. 
*, fJ < O.OS. 
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Human premalignant oral lesion tissue exhibits a dramatic increase in levels of IFN-y, 
IL-2, and IL-17 A compared to both normal/adjacent and HNSCC tissue, while human 
HNSCC tissue exhibits a simultaneous increase in levels of IFN-y and IL-l 0 compared to 
control tissue 
To investigate the local levels ofTh1, Th17, and Th2 cytokines in humans, 
normal/adjacent tongue tissue, premalignant tissue, and HNSCC tumor tissue was 
obtained from patients, mechanically lysed, and analyzed by cytokine bead array for 
the presence of the Th1 cytokines IFN -y and IL-2, the Th17 cytokine IL-17 A, and the 
Th2 cytokines IL-4 and IL-10 (Fig 3.8a). Levels of cytokine were normalized to 
pg/l00Jlg of protein .. as determined by BeA protein assay. To investigate the 
systemic levels of Th 1, Th17 .. and Th2 cytokines in humans, peripheral blood was 
obtained from normal patients and patients with either premalignant lesions or 
HNSCC .. and plasma was also analyzed by cytokine bead array for presence of IFN-y, 
IL-2, IL-17 A, IL-4, and IL-I0 (Fig 3.8b). While no difference was detected between 
plasma levels of IFN-y and IL-2 for all three groups .. premalignant lesion tissue was 
found to contain a great deal more of both of these Thl cytokines compared to both 
normal/adjacent and HNSCC tissue (Fig 3.8a). Unexpectedly, HNSCC tissue was 
found to have a significant increase in IFN-y compared to normal/adjacent tissue 
(Fig 3.8a). Analysis of IL-17 A revealed a significant decrease in this cytokine in the 
plasma of HNSCC patients compared to controls and a sizeable Significant increase 
in this cytokine in premalignant tissue compared to both normal/adjacent and 
HNSCC tissue (Fig 3.8a and b). Finally .. while IL-4levels were found to be 
undetectable in both plasma and tissue, analysis of the Th2 cytokine IL-I0 showed a 
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trend towards an increase in the level of this cytokine in the plasma of HNSCC 
patients compared to controls and a significant increase in the level of this cytokine 
in the HNSCC tissue compared to normal/adjacent tissue (Fig 3.8a and b). This data 
indicates that, as observed in mice, human premalignant tissue is associated with a 
large increase in inflammatory Thl and Th17 cytokines. While human HNSCC tissue 
is associated with the expected increase in the immunosuppressive cytokine IL-I0, 
it is also unexpectedly associated with an increase in the Th 1 cytokine IFN-y 
compared to normal/adjacent controls. 
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Fig 3.8 Levels of IFN-y, IL-2, and IL-17 A are increased in human premalignant 
tissue compared to normal/adjacent human tissue and human UNsee tissue, 
while levels of IFN-y and IL-i0 in UNSee tissue are increased compared to 
normal/adjacent controls. 
Cytometric bead array analysis of human normal/adjacent, premalignant, and 
HNSCC tissue lysate, with normalization to 100 Jlg of protein (as determined by BCA 
protein assay), with at least 6 samples per group (a), and cytometric bead array 
analysis of plasma from normal, premalignant lesion-bearing, and HNSCC-bearing 
patients, with at least 23 samples per group (b). *, p < O.OS. ***, P < 0.001. 
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3.4 Discussion 
Depending on a multitude of factors, the immune system is capable of either 
mounting a beneficial response against dysplastic cells or promoting tumor 
development and progression. As each individual component of an immune 
response is not always consistently beneficial or detrimental, it is essential to 
investigate the changes in immune phenotype during different mechanisms of 
tumor initiation and development for different types of malignancies. This study 
examined the alterations in various immune populations during carcinogen-induced 
development of premalignant oral lesions and HNSCC. The development of oral 
premalignant lesions is shown to be associated with an increase in percentage of 
conventional lymphocytes expressing activation and memory markers in cervical 
lymph nodes of 4NQO-treated mice compared to both control and HNSCC-bearing 
mice, changes that are not accompanied by a significant increase in regulatory T 
cells. Specifically, no significant difference was detected between percentages of 
Teonv cells positive for the early activation marker CD69, a glycoprotein expressed 
within an hour after stimulation which rapidly declines after 4-6 hours, while levels 
ofTconv cells positive for CD25, a marker induced within 2-24 hours of stimulation 
which persists for a few days after stimulus withdrawal, and Tconv cells with 
upregulated CD44, an adhesion molecule upregulated on T cells after activation with 
antigen and maintained until memory cell death, were both increased in lymph 
nodes from premalignant lesion-bearing mice compared to control mice and 
HNSCC-bearing mice (201, 206, 207). This data indicates that, at the time when 
lesions become detectable, an immune response has been mounted in the dysplastic 
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tissue and has been present for some time. In addition, lymph node cells from 
premalignant lesion-bearing mice have a minor, yet significant, increase in Tconv 
cells bearing the exhaustion marker KLRG1, a receptor upregulated by T cells upon 
repetitive antigenic stimulation which induces T cell proliferative dysfunction, and a 
trend towards an increase in Tconv cells bearing the exhaustion marker PD-l, an 
inhibitory receptor upregulated during chronic T cell stimulation which induces T 
cell unresponsiveness, compared to both control and HNSCC-bearing mice (202, 
208-211). Also, while the premalignant stage is not associated with a significant 
decrease in conventional T cells or a significant increase in regulatory T cells, the 
ratio of CD4+ conventional to regulatory T cells is decreased compared to control to 
an extent that matches the CD4+ conventional to regulatory T cell ratio of HNSCC-
bearing mice. In addition, the proliferative capacity of CD4+ conventional T cells and 
the suppressive capacity of the CD4+ regulatory T cells appears to progressively 
decrease throughout the development of HNSCC. This data indicates that, by the 
time lesions become detectable, the immune reaction might already be starting the 
transition toward the immune environment seen in the setting of HNSCC. 
The classical view of immunoediting typically identifies a beneficial 
antitumor response as involving an increase in IFN-y secreting Thl and Tcl cells 
with a concurrent decrease in Th2 cells (203). A shift in the opposite direction is 
often seen in peripheral blood and tumor-infiltrating cells of cancer patients. The 
current study reveals that both mice with oral premalignant lesions and, 
unexpectedly, mice with HNSCC exhibit an increased Thl and Tcl response without 
any concomitant change in Th2 response compared to control. Likewise, human 
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premalignant tissue and HNSCC tissue was found to have an increase in IFN-y levels 
compared to normal/adjacent controls. This data contradicts earlier human studies 
showing a local and systemic skewing from a Thl response to a Th2 response in 
patients with HNSCC (28, 176). This brings up two major questions: #1) is the Thl 
and Tcl response that is so elevated in the setting of HNSCC actually promoting 
tumor growth, and #2) is the Thl and Tcl response at the premalignant stage 
performing the same role as the Thl and Tcl response observed at the HNSCC 
stage? Interferon-y expression has previously been shown to be associated with 
tumor promotion (120, 121, 212 .. 213) .. notably in carcinogen-induced tumors of 
epithelial origin (212) and involving upregulated Th17 expression (121). In 
addition, the timing of the Th1 and Tcl response may discern between different 
purposes of the response. It is interesting to note that the IFN -y related response at 
the premalignant stage is characterized by an increase in Tcl cells to a greater 
extent than the increase in Thl cells, while the IFN-y response at the HNSCC stage 
shifts to a Th 1-dominated reaction. Perhaps the source of the IFN -y is significant in 
defining its role in the anti- or pro-tumor immune response. Further investigation 
into the specific roles of Th1 cells, Tcl cells, and IFN -y during tumor development 
and progression will help elucidate its role in the tumor microenvironment in 
4NQO-induced HNSCC carcinogenesis. 
The role of the Th 17 population remains somewhat ambiguous; some studies 
have indicated that these cells can work with Th1 cells to help eliminate 
malignancies while other studies have identified Th17 cells as tumor-promoting, 
often citing their pro-angiogenic effects (204, 205). This study revealed that the 
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Th17 response increases in mice and humans bearing premalignant lesions 
compared to controls, and then falls in mice and humans bearing HNSCC. This could 
indicate that the Th 17 response seen during early development of HNSCC 
represents an anti-tumor response. As Tregs and Th17 cells have been shown to 
have an inversely proportional relationship (214), the decrease in Th17 cells seen in 
HNSCC-bearing mice may be related to the simultaneous increase in the Treg 
popUlation. It will be important to determine the relationship between these two 
populations during the progression to HNSCC with future experimentation. In 
addition, mice bearing premalignant lesions were found to have an increase in a 
CD4-, IL-17 A-expressing population of cells that does not appear to be Tc17 cells 
(Fig 3.6a). Determining the identity of this cell population through costaining for IL-
17 A and other cells known to occasionally express IL-17 A, such as yo T cells or mast 
cells (215, 216), will be important for future investigation into the functional 
implications of IL-17 A-producing populations during HNSCC carcingogenesis. 
We have evaluated the multitude of immune reactions in 4NQO-treated mice 
during the development of HNSCC, and we have begun to evaluate these same 
reactions in humans during the development of HNSCC. At this point, it is essential 
to investigate the functional impact of the individual cell populations that are 
upregulated at the premalignant stage or after HNSCC establishment. This can be 
accomplished through analysis of tumor progression in 4NQO-treated mice with 
depleted CD4 .. CD8 .. or CD4 and CD8 cells. Investigation into the role of IFN -y in the 
progression of HNSCC can be carried out in mice with depleted or neutralized IFN-y. 
Future studies will help to elucidate the links between these cell subsets and tumor 
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development. Investigation into whether the responses described in this study are 
beneficial in any way, and if they can be further manipulated to combat tumor 
progression, is highly important to developing new treatment strategies for HNSCC. 
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CHAPTER 4: DENDRITIC CELL VACCINATION OF PREMALIGNANT 
LESION-BEARING MICE 
Aim 2: To use premalignant lesion-pulsed dendritic cells in vivo to skew the 
immune phenotype within mice bearing premalignant lesions towards 
immunity against further development a/premalignant oral lesions and 
progression to HNSCC. 
4.1 Introduction 
Head and neck squamous cell carcinoma (HNSCC) is an aggressive 
malignancy that has had a 5-year survival rate of around 50% for over 30 years 
(173 J 217). Developing from oral keratinizing epithelial cells in a progressive 
fashion, both premalignant oral lesions and HNSCC have a high incidence of 
recurrence. This malignancy has also been consistently associated with extensive 
immune manipulation, including upregulation of both immunosuppressive 
regulatory T cells and inflammatory cell types (163 J 164, 176, 177, 218, 219). The 
high incidence of recurrence and systemic immune manipulation are large 
contributors to the low survival rate of HNSCC (173, 186, 217). 
Dendritic cell vaccination involves the exposure of dendritic cells to tumor-
associated antigens (TAAs) through one of a variety of mechanisms. Primed 
dendritic cells are then matured and injected into the recipient with the intention of 
stimulating the recipient's own T cells to specifically target tumor tissue (220). In 
the case of HNSCC, however, the patient's immune system at the point of initiation of 
immunotherapy may have been compromised to the point that it is not capable of 
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mounting a sufficient immune response to vaccination. While established HNSCC 
has been shown to be associated with extensive immune manipulation, during the 
premalignant stages of progression, levels of activated T cells with a memory 
phenotype, including inflammatory Thl, Tcl and Th17 cells increase (218). As such, 
this time may be optimal for initiation of immunotherapeutic techniques, since the 
immune system is already stimulated. 
The utilization of this technique during the premalignant stage of HNSCC 
depends on the presence of common antigens that are upregulated at both the 
premalignant and malignant stages compared to normal tissue. Our lab identified 
several common TAAs, including EGFR, RAGE, and MUC1, in mice with 4NQO 
carcinogen-induced premalignant oral lesions and HNSCC, as well as in patients 
(136,180). Previous work also revealed that in vitro sensitization of human PBML 
with autologous premalignant lesion lysate resulted in increased IFN-y release from 
sensitized PBML upon subsequent challenge with autologous premalignant lesion or 
HNSCC lysate and increased cytolytic activity of sensitized PBML against challenge 
with premalignant lesion or HNSCC cells (136). Additional in vitro work showed 
that sensitization of mouse splenocytes with premalignant lesion lysate-pUlsed 
dendritic cells resulted in increased IFN-y release from sensitized splenocytes upon 
subsequent challenge with premalignant lesion or HNSCC lysate (180). This 
provides the rationale for the use of premalignant tissue as the source of antigen to 
stimulate a protective immune response against the further development of 
premalignant lesions and HNSCC. 
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In the current study, mice treated with 4NQO until the development of 
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premalignant oral lesions were vaccinated with dendritic cells pulsed with either 
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premalignant lesion lysate or normal tongue epithelium lysate. Lysate was used as 
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an antigenic source to provide an increased amount of potentially immunogenic 
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antigens that the dendritic cells could present, rather than limiting presentation to 
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one specific antigen. As mUltiple rounds of splenocyte sensitizations was required 
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for activation in previous in vitro studies (180), three separate vaccinations were 
Chapter 4 65 DC Vaccination of Premalignant Lesion-Bearing Mice 
Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination 
administered: the first was given at the onset of premalignant lesions, the second 
was given 1 week after the first, and the final booster was given 7 weeks after the 
first (Fig 4.1). To determine immune response in vaccinated mice over time, mice 
were sacrificed at two timepoints: an early timepoint at 4 weeks after the first 
vaccination and a late timepoint at 8 weeks after the first vaccination (1 week after 
the final booster) (Fig 4.1). Lesion progression as well as immune response to 
vaccination was monitored. Somewhat surprisingly, both mice treated with the 
premalignant lesion-pulsed dendritic cell vaccine (DCpm) and, to a lesser extent, 
2 Month old C5781/6 Mouse 
Identified premalignant oral lesions 
BM-derived mDCs II Identified oral HNSCC 






Sack at 4 
weeks 
Sack at 8 
weeks 
Fig 4.1 Representation of vaccination schedule. 
mice treated with the normal tongue epithelium lysate-pulsed dendritic cells (DCnt) 
had an improved clinical course compared to 4NQO-treated controls. DCnt mice had 
an early increase in cervical lymph node cellularity and levels of multiple immune 
effectors, while DCpm treated mice had a delayed increase in these same effectors. 
Chapter 4 66 DC Vaccination of Premalignant Lesion-Bearing Mice 
Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination 
Chapter 4 67 DC Vaccination of Premalignant Lesion-Bearing Mice 
Premalignant Oral Lesion Immunobiology: Immune Modulation and Vaccination 
4.2 Materials and Methods 
Oral HNSCC carcinogenesis 
Five mg/ml 4NQO was administered in the drinking water (diluted to 50 
j.lg/ml) of 2 month old (at start) female C57BL/6 mice (Charles Rivers Laboratory, 
Wilmington, MA)) until development of premalignant oral lesions (6-8 weeks) or 
HNSCC (12-16 weeks). Control mice received propylene glycol diluent control. To 
monitor development of premalignant oral lesions and HNSCC, oral cavities of 
4NQO-treated mice were endoscoped weekly using a Stryker 1.9mm x 30° scope and 
a Stryker 1088 HD camera. Mice were sedated with inhaled isoflurane (Pi ramal 
Healthcare, Mumbai, India) during the procedure. 
Dendritic cell generation .. pulsing .. and maturation 
Cells were collected from C57BI/6 mouse femoral bone marrow and cultured 
for 5-6 days with 1000 U/ml GM-CSF (R&D Systems, Minneapolis, MN) to stimulate 
the development of dendritic cells. Dendritic cells were pulsed by 12 hours of 
incubation with 25 f..lg/mllysate of premalignant lesion-bearing tissue from 4NQO-
treated mice or normal tongue epithelial tissue from control mice. Tongue 
epithelium was obtained after incubation of tongue fragments with Dispase II 
(Roche, Florence, SC) and lysed through sonication, after which protein 
concentration was determined by BCA protein assay (Pierce, Rockford, IL) per 
manufacturer's instructions. Dendritic cells were then matured by 48 hrs of culture 
with 10 ng/ml GM-CSF and 0.1 ~g/ml LPS (R&D Systems, Minneapolis, MN). 
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Vaccine regimen 
Vaccination was by injection of lxl06 bone marrow-derived premalignant 
lesion lysate- or normal tongue epithelium lysate-pulsed dendritic cells in SO J..lI 
serum-free medium into the ventral tongue of 4NQO-treated mice under inhaled 
isoflurane sedation (Piramal Healthcare, Mumbai, India). 4NQO-treated controls 
were injected with SO III of saline into the ventral tongue of 4NQO-treated mice. The 
first vaccination was given to mice once all 4NQO-treated mice were determined 
through oral cavity endoscopy to exhibit premalignant oral lesions. A second 
vaccination was administered 7 days after the first. Some mouse groups were 
sacrificed four weeks following the first vaccination. A third vaccination was 
administered 7 weeks after the first vaccination for the remaining mice, and these 
mice were sacrificed 7 days later. Tongues were harvested, sectioned, and stained 
with hematoxylin and eosin for histologic analysis. 
Cervical lymph node processing 
Cervical lymph nodes were harvested from mice and homogenized via a 
Stomacher 80 homogenizer (Seward, West Sussex, UK) set on high for 90 sec. Cells 
were passed through a 40-J..lm cell strainer (BD Falcon, San Jose, CA) and rinsed with 
Hank's Buffered Saline Solution (HBSS, Invitrogen, Carlsbad, CA) to remove debris. 
Cell number was determined by counting cells excluding trypan blue using a 
hemocytometer. 
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Flow cytometric analysis of surface markers and Foxp3 expression 
All reagents in this section were from BD Bioscience (San Jose, CA) unless 
otherwise stated. In order to detect levels of CD8 and CD4 positive cells in relation 
to Foxp3, ex vivo cervical lymph node cells in single-cell suspension were washed 
once in Stain Buffer and resuspended at lxl0 7 cells/ml. In order to detect 
expression ofMHCII (I-Ab for C57/b16 mice), CD80, and CD86 on CDllc positive 
dendritic cells, cultured matured dendritic cells in single-cell suspension were 
washed once in Stain Buffer and resuspended at lxl0 7 cells/ml. Nonspecific 
staining oftotallxl06 cells was blocked with FBS and anti-CD16/32 monoclonal 
antibody prior to cell surface staining with the following antibodies: PerCP-Cy5.5 
CD4, FITC CDBa, FITC CDllc, PE C025, PE I-Ab, APC CD69, APC CD80, and PE-Cy7 
CD86. Intracellular staining for PE-Cy7 Foxp3 was performed after fixation with 
Foxp3 Fixation Buffer and permeabilization with Foxp3 Permeabilization Buffer. 
Extent and frequency of positively stained cells was visualized using flow cytometry 
(FACSCanto, San Jose, CA). 
Flow cytometric analysis ofcytokine expression 
All reagents in this section were from BD Bioscience (San Jose, CA) unless 
otherwise stated. In order to detect intracell ular cytokines, single-cell suspensions 
of cervical lymph node cells were restimulated for 4 hours at 37°C with 50 ng/ml 
phorbol 12-myristate 12-acetate (PMA), 1 Jlg/ml ionomycin, and brefelden A 
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solution. Nonspecific staining of total of lxl06 cells was blocked with FBS and anti-
CD16/32 monoclonal antibody prior to cell surface staining with the following 
antibodies: PerCP-CyS.S CD4 and PE-Cy7 CD8a. Intracellular staining for PE IL-17 A, 
FITC IFN-y, APC IL-4, APC IL-I0 and Alexa Fluor 488 IL-13 (eBioscience} San Diego, 
CA) was performed after fixation/permeabilization with Cytofix/Cytoperm. Extent 
and frequency of positively stained cells was visualized using flow cytometry 
(FACSCanto, San Jose} CA). 
Cytokine bead array 
All reagents in this section were from BD Bioscience (San Jose, CA) unless 
otherwise stated. In order to detect cytokines released into supernatant, single-cell 
suspensions of cervical lymph node cells or dendritic cells were restimulated for 4 
hours at 37°C with 50 ng/ml PMA and 1 I-lg/ml ionomycin without addition of 
brefeldin A or cervical lymph node cells were activated for 3 days in the presence of 
anti-CD3/anti-CD28 beads. To determine degree of cytokine release in response to 
challenge, some lymph node cells were incubated for three days with 25fl.g/ml of 
normal tongue epithelium lysate, premalignant epithelium lysate or HNSCC 
epithelium lysate in the presence of anti-CD3/anti-CD28 beads. Presence/level of 
IFN-y, IL-17 A, IL-4, IL-IO} and IL-13 in lymph node cell supernatant and IL-12, IL-6, 
TNF, IL-I0, IL-la and IL-lf3 in dendritic cell supernatant was determined using a 
mouse cytometric bead array Thl/Th2/Th17 cytokine kit and cytometric bead 
array flex sets for individual cytokines according to the manufacturer's instructions. 
Relative amount of each cytokine was analyzed using FCAP Array software. 
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Statistical analysis 
Data were reported using the mean as a measure of central tendency ± 
standard error of the mean. To compare one variable condition between groups, the 
2-tailed Student's t-test was used. To evaluate significant differences between lesion 
numbers for each mouse group, the Mann-Whitney U Test was used. To evaluate if 
any significant differences exist between histologic scores, a chi squared test was 
used. Significance was reported in the 95% confidence interval. 
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4.3 Results 
DCpm vaccination and, to a lesser extent, Dent vaccination result in an improved 
clinical response compared to 4NQO-treated controls. 
The ultimate goal of any interventional immunotherapeutic approach is an 
improvement in clinical status. To monitor development of lesions in 4NQO-treated 
mice, oral cavities were examined through weekly endoscopy and number of visible 
lesions was counted. Analysis of lesion number revealed that DCpm vaccination 
resulted in a significant decrease in the number of lesions compared to 4NQO 
control at 6, 7, and 8 weeks (Fig 4.2a). DCnt vaccination resulted in a significant 
decrease in number of lesions compared to 4NQO control at 8 weeks only (Fig 4.2a). 
Mice were sacrificed at 4 and 8 weeks post-vaccination and tongues were 
harvested, processed, and random paraffin-embedded sections were analyzed for 
histologic score (normal, mild dysplasia, moderate-severe dysplasia, invasive 
carcinoma). Histologic analysis revealed a trend towards an increase in the overall 
degree of dysplasia at 4 weeks in mice administered the Dent vaccine compared to 
4NQO-treated controls. Similar to the results from gross analysis, histologic analysis 
also revealed a trend towards a decrease in the overall degree of dysplasia at 8 
weeks in mice administered either the DCnt or DCpm vaccine compared to 4NQO-
treated controls (Fig 4.2b). This indicates that DCpm vaccination may decrease the 
clinical lesion burden in mice treated with 4NQO, and, surprisingly, DCnt 
vaccination also appears to decrease clinical lesion burden, though at a later 
timepoint. 
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Fig 4.2 DCpm vaccination and DCnt vaccination result in an improved clinical 
response compared to 4NQO-treated controls. 
Number of visible lesions (a) as determined by weekly endoscopy of oral cavities of 
4NQO-treated mice administered dendritic cells pulsed with normal tongue 
epithelium lysate (DCnt), dendritic cells pulsed with premalignant lesion lysate 
(DCpm), or saline (4NQO Ctl) with at least 15 mice per groups. Data represent 
mean ± SEM. *, P < 0.05. **, p < 0.01. ***, P < 0.001 (Mann-Whitney U test) . At 4 
weeks and 8 weeks post-first vaccination, 4NQO Ctl, DCnt and DCpm mice were 
sacrificed and tongues were harvested, sectioned, and random sections were 
stained with hematoxylin and eosin for histopathologic analysis (b) with tongues 
from at least 11 mice per group. Data represent percentage, and statistical 
sie:nificance was determined bv chi sauared test. 
DCnt vaccination results in an early increase in lymph node cell count, while DCpm 
vaccination results in a delayed increase in lymph node cell count. 
The development of malignancies is often associated with hyperplasia of 
draining lymph nodes, whether due to reactive hyperplasia, metastasis, or both 
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(195). To determine the degree of lymph node hyperplasia among the various 
mouse groups, cervical lymph nodes from control mice, 4NQO-treated control mice, 
4NQO-treated Dent mice, and 4NQO-treated DCpm mice were harvested at 4 and 8 
weeks post-first vaccination, and the number of try pan blue-excluding cells were 
counted. At 4 weeks post-first vaccination, DCnt vaccinated mouse lymph nodes 
contained significantly more cells than all other groups (Fig 4.3a). At 8 weeks post-
first vaccination, however, DCpm and DCnt vaccinated mouse lymph nodes 
contained greater numbers of cells compared to control and 4NQO control mouse 
lymph nodes (Fig 4.3b). Also at 8 weeks .. 4NQO control mouse cervical lymph nodes 
contained significantly more cells than control mice (Fig 4.3b). This indicates that 
there is a more rapid response in lymph node cell proliferation after Dent 
vaccination compared to DCpm vaccination. However, the proliferative response to 
the DCpm vaccine occurs to a great extent by the later timepoint. 
Dent vaccination results in an early increase in levels of Tconv cells and CD4 TregsJ 
while both DCnt and DCpm vaccination result in a decreased percentage ofCD4 Tconv 
cells and increased absolute number of CDB Tconv cells and Tregs at 8 weeks 
compared to 4NQO-treated controls. 
Many solid carcinomas have been shown to be associated with local and 
systemic immunosuppression (163, 164 .. 176). This includes downregulation of 
stimulatory immune cells, such as CD4+ and CD8+ conventional T cells, and 
upregulation of suppressive immune cells. One suppressive cell population that is 
often upregulated as a part of this phenomenon is the regulatory T cell population, 
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Fig 4.3. DCnt vaccination results in an early increase in lymph node 
cellularity, while DCpm vaccination results in a delayed increase in lymph 
node cellularity. 
At 4 weeks and 8 weeks post-first vaccination} control mice} 4NQO-treated control 
mice (4NQO Ctl)} DCnt-vaccinated mice (DCnt) and DCpm-vaccinated mice (DCpm) 
were sacrificed and cervical lymph nodes were harvested and processed to single-
cell suspensions} and trypan-blue excluding cells were counted with at least 5 mice 
per group. Data represent mean ± SEM of cell number at 4 weeks post-first 
vaccination (a) and 8 weeks post-first vaccination (b). *} p < 0.05. **} p < 0.01. ***} P 
< 0.001 (2-tailed Studenfs t-test). 
identified by expression of the transcription factor Foxp3 (163} 164} 176). Our lab 
had previously shown that locoregional regulatory and conventional T cell numbers 
are both increased in mice with HNSCC (218). To determine the relative 
composition of conventional and regulatory T cells in 4NQO-treated mice 
administered DC vaccination} lymph node cells collected at 4 and 8 weeks post-first 
vaccination were stained for surface expression of CD4 and CD8 and intracellular 
expression of Foxp3. Proportions of cells expressing each marker were determined 
through flow cytometric analysis} and numbers of cells expressing each markers 
were determined by multiplying the percent positive by the number of lymph node 
cells for each individual mouse. At 4 weeks post-first vaccination} a1l4NQO-treated 
mouse groups had a decreased percentage of Foxp3- CD4+ Tconv cells and an 
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increased percentage of CD4+ Treg cells compared to controls (Fig 4.4a and b). At 
this timepoint, DCnt mice exhibited an increase in percentage and absolute number 
of Tconv cells and an increase in absolute number of CD4 Tregs compared to 4NQO-
treated controls (Fig 4.4c). At 8 weeks post-first vaccination, both DCnt and DCpm 
mice exhibited a decrease in percentage of CD4+ Teonv cells compared to 4NQO 
controls (Fig 4.4a and b). Analysis of cell numbers revealed an increase in the 
absolute number of CD8 Tconv cells and Treg cells in both DCnt and DCpm mouse 
lymph nodes compared to 4NQO controls (Fig 4.4c). This data indicates that DCnt 
vaccination may work early on to stimulate an increase in Tconv and Treg cells. 
While DCpm mice show no differences from 4NQO controls early on .. DCpm 
vaccination appeared to affect a delayed increase in Tconv and Treg cells at 8 weeks 
after the initial vaccination. 
Dent vaccinated mice exhibit a decrease in percentage but increase in absolute 
number of activated CD4 Tconv cells 4 weeks, while both Dent and DCpm vaccinated 
mice exhibit an increase in absolute number of activated CDB Tconv cells at B weeks 
compared to 4NQO-treated controls. 
An optimal immune response to antigenic stimulation involves the activation 
of conventional T cells (198). To determine the proportions of conventional T cells 
bearing markers for activation, CD4+Foxp3- and CD8+Foxp3- T lymph node cells 
were analyzed for expression of CD25 and CD44. While often used as a marker for 
regulatory T cells, CD25 expression on foxp3- conventional T cells is expressed 
within 2-24 hours after stimulation and persists for a few days after withdrawal of 
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Fig 4.4 DCnt vaccination results in an increase in levels of Tconv cells and CD4 
Tregs at 4 weeks, while both DCnt and DCpm vaccination result in a decreased 
percentage of CD4 Tconv cells and increased absolute number of CDB Tconv 
cells and Tregs at B weeks compared to 4NQO-treated controls. 
Representative results (a) and graphical representation (b) of flow cytometric 
staining of cervical lymph node cells from control, 4NQO-treated control (4NQO Ctl), 
DCnt-vaccinated (DCnt) and DCpm-vaccinated (DCpm) mice at 4 and 8 weeks post-
first vaccination with at least 5 mice per group. Data represent mean ± SEM. *, P < 
0.05. **, p < 0.01 (2-tailed Student's t-test). Total numbers of populations (c) were 
determined by multiplying the percent positive by the number of cervical lymph 
node cells for each individual mouse. Data represent mean ± SEM. *, P < 0.05. **, p 
< 0.01. ***, P < 0.001 (2-tailed Student's t-test). 
the stimulus. CD44 is a glycoprotein involved in cell adhesion and migration, and its 
increased expression is indicative ofT cell antigen experience (200, 201). 
Percentages of cells bearing CD25 and CD44 were determined by flow cytometric 
analysis, and total numbers of cells bearing these markers were determined by 
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multiplying percent positive by the number of lymph node cells for each individual 
mouse. At 4 weeks post-first vaccination, percentages of CD25+ and CD44hi CD4 and 
CD8 Tconv cells are decreased in Dent mouse lymph nodes compared to 4NQO 
controls (Fig 4.5a and b). After factoring in cell numbers, DCnt vaccinated mouse 
lymph nodes were found to have an increased absolute number of CD25+ and CD44hi 
CD4 Tconv cells compared to 4NQO controls (Fig 4.5c). At this timepoint, the only 
significant difference between the DCpm and 4NQO control group is a decrease in 
percentage of CD44hi COB Tconv cells in DCpm-vaccinated mice (Fig 4.5a and b). 
This could possibly be due to antigen-specific cells dying upon TCR restimulation in 
vivo. At 8 weeks post-first vaccination, both vaccinated groups see a significant 
increase in number of CD2S+ and CD44hi CD8 Tconv cells compared to 4NQO 
controls, and DCpm-vaccinated mice also exhibit an increase in CD44hi CD4 Tconv 
cells compared to 4NQO controls (Fig 4.5c). This data indicates that both DCnt and 
DCpm vaccination tend to result in an increase in activated T cells compared to 
4NQO treatment alone by 8 weeks post-first vaccination. 
DCnt vaccination results in an early increase in Thl and Tel levelsl while both DCnt 
and DCpm vaccination result in an increase in Tel levels at 8 weeks compared to 
4NQO-treated controls. 
T cells can be further subdivided based on their expression of certain 
cytokines that dictate differing effector functions. Thl cells (and a smaller subset of 
CD8+ cells known as Tcl cells) secrete IFN-y and are generally considered as 
inflammatory. They are traditionally thought of as beneficial for anti-tumor 
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Fig 4.5 DCnt vaccinated mice exhibit a decrease in percentage but increase in 
absolute number of activated CD4 Tconv cells 4 weeks, while both DCnt and 
DCpm vaccinated mice exhibit an increase in absolute number of activated 
CD8 Tconv cells at 8 weeks compared to 4NQO-treated controls. 
Representative results (a) and graphical representation (b) of flow cytometric 
staining of cervical lymph node cells from control, 4NQO-treated control (4NQO Ctl), 
DCnt-vaccinated (DCnt) and DCpm-vaccinated (DCpm) mice at 4 and 8 weeks post-
first vaccination with at least 5 mice per group. Data represent mean ± SEM. *, P < 
0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Total numbers of 
populations (c) were determined by multiplying the percent positive by the number 
of cervical lymph node cells for each individual mouse. Data represent mean ± SEM. 
*, P < 0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). 
immunity (203). However, recent research in our laboratory has shown that Thl 
and Tcl cells are upregulated in both the premalignant and malignant stages of 
HNSCC (218). To evaluate the populations ofThl and Tcl cells in draining lymph 
nodes of control, 4NQO control, DCnt, and DCpm mice, lymph node cells were 
stained for surface expression of CD4 and CDB and intracellular expression of the 
Thl and Tcl cytokine IFN-y after 4 hours incubation with PMA, Ionomycin and 
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brefeldin A .. In addition, supernatants of lymph node cells incubated for 4 hours in 
PMA and Ionomycin were analyzed by cytometric bead array for levels of IFN-y. At 
4 weeks post-first vaccination, lymph nodes from DCnt vaccinated mice contain a 
greater percentage and number ofThl cells and a greater absolute number ofTcl 
cells compared to all other groups (Fig 4.6a, b, c). This is supported by CBA data 
showing an increase in IFN-y released into the supernatant of Dent mouse lymph 
node cells compared to all other groups (Fig 4.6d). 
At 8 weeks post-first vaccination, DCnt mouse lymph nodes have a decreased 
percentage ofThl cells and an increased percentage ofTcl cells compared to 4NQO 
controls (Fig 4.6a and b). After factoring in cell number, both DCnt and DCpm 
mouse lymph nodes were found to contain a greater absolute number ofTcl cells 
compared to 4NQO controls (Fig 4.6c). Analysis of cytokines secreted in response to 
4 hour stimulation with PMA and Ionomycin revealed no significant changes in the 
levels of IFN-y in the supernatant of ex vivo lymph node cells from vaccinated mice 
compared to 4NQO controls (Fig 4.6d). To determine cytokine release in response 
to more extended stimulation, lymph node cells from 8 week post-first vaccination 
mice were cultured for 3 days in the presence of anti-CD3/anti-CD28. After the 
three day stimulation, cytometric bead array was used to measure levels of IFN-y in 
the supernatant. Cytokine analysis revealed a huge increase in IFN-y levels in the 
supernatant of DCpm and Dent mouse lymph node cells compared to control and 
4NQO control (Fig 4.6e). This data indicates that Dent vaccination induces an early 
increase in Thl and Tcl cells, but by the later timepoint, both DCnt and DCpm 
vaccination induce a Tcl-type reaction. 
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Fig 4.6 DCnt vaccination results in an increase in Thl and Tcllevels at 4 
weeks, while both DCnt and DCpm vaccination result in an increase in Tcl 
levels at 8 weeks compared to 4NQO-treated controls. 
Representative results (a) and graphical representation (b) of flow cytometric 
staining of cervical lymph node cells from control, 4NQO-treated control (4NQO Ctl), 
DCnt-vaccinated (DCnt) and DCpm-vaccinated (DCpm) mice at 4 and 8 weeks post-
first vaccination with at least 5 mice per group. Data represent mean ± SEM. *, P < 
0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Total numbers of 
populations (c) were determined by multiplying the percent positive by the number 
of cervical lymph node cells for each individual mouse. Data represent mean ± SEM. 
*, P < 0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Cytometric bead 
array analysis (d) of supernatant of 4 week and 8 week control, 4NQO Ctl, DCnt, and 
DCpm mouse cervical lymph node cells after stimulation for four hours with PMA 
and ionomycin, with at least 5 mice per group. Data represent mean ± SEM. *, P < 
0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Cytometric bead array 
analysis (e) of supernatant of 8 week control, 4NQO CtI, DCnt, and DCpm mouse 
cervical lymph node cells after 3 day stimulation with anti-CD3/anti-CD28 beads 
with at least 4 mice per group. Data represent mean ± SEM. *, P < 0.05 (2-tailed 
Student's t-test). 
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Dent vaccination results in an early increase in absolute number ofTh17 and Tc17 
cells, while both DCnt and DCpm vaccination result in an increase in absolute number 
ofTh17 and Tc17 cells at 8 weeks compared to 4NQO-treated controls. 
Th17 cells (and a smaller subset of CD8+ cells known as Tcl7 cells) secrete 
IL-17 A, among other cytokines, and induce a greater degree of inflammation 
compared to Thl cells. Their role in antitumor immunity is less clear. They are 
highly proinflammatory and proangiogenic, qualities that generally promote 
tumorigenesis. They are also upregulated in many different tumor types; however, 
in some tumor types, like lung cancer and ovarian cancer .. an increased presence of 
IL-17 A and Th17 cells is actually associated with improved prognosis (123, 125, 
204,205). Recent data from our lab showed that Th17 cells are highly upregulated 
in mice bearing premalignant oral lesions, only to decrease in the draining lymph 
nodes of HNSCC-bearing mice (218). To evaluate the populations ofTh17 and Tc17 
cells in draining lymph nodes of control, 4NQO control, DCnt, and DCpm mice, lymph 
node cells were stained for surface expression of CD4 and CDB and intracellular 
expression of the Th17 and Tcl7 cytokine IL-l7a after 4 hours incubation with PMA, 
Ionomycin and brefeldin A. In addition, supernatants of lymph node cells incubated 
for 4 hours in PMA and Ionomycin were analyzed by cytometric bead array for 
levels of IL-17 A. At 4 weeks post-first vaccination, Dent mouse lymph nodes have 
an increased absolute number of Th17 and Tcl7 cells compared to 4NQO controls, 
corresponding to an increased secretion of IL-17 A from Dent lymph node cells 
compared to 4NQO lymph node cells in response to 4 hour stimulation (Fig 4.7c and 
d). 
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Fig 4.7 DCnt vaccination results in an increase in absolute number of Th17 
and Tc17 cells at 4 weeks, while both DCnt and DCpm vaccination result in an 
increase in absolute number of Th17 and Tc17 cells at 8 weeks compared to 
4NQO-treated controls. 
Representative results (a) and graphical representation (b) of flow cytometric 
staining of cervical lymph node cells from control, 4NQO-treated control (4NQO Ctl), 
DCnt-vaccinated (DCnt) and DCpm-vaccinated (DCpm) mice at 4 and 8 weeks post-
first vaccination with at least 5 mice per group. Data represent mean ± SEM. No 
significant differences were found in percentages of CD4 + IL-17 A + or CD8+ IL-17 A + 
cells at 4 or 8 weeks (2-tailed Student's t-test). Total numbers of populations (c) 
were determined by multiplying the percent positive by the number of cervical 
lymph node cells for each individual mouse. Data represent mean ± SEM. *, P < 
0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Cytometric bead array 
analysis (d) of supernatant of 4 week and 8 week control, 4NQO Ctl, DCnt, and 
DCpm mouse cervical lymph node cells after stimulation for four hours with PMA 
and ionomycin, with at least 5 mice per group. Data represent mean ± SEM. *, P < 
0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Cytometric bead array 
analysis (e) of supernatant of 8 week control, 4NQO Ctl, DCnt, and DCpm mouse 
cervical lymph node cells after 3 day stimulation with anti-CD3/anti-CD28 beads 
with at least 4 mice per group. Data represent mean ± SEM. *, P < 0.05 (2-tailed 
Student's t-test1. 
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At 8 weeks post-first vaccination, both DCnt and DCpm mice have an 
increased absolute number ofTh17 and Tc17 cells compared to control and 4NQO 
control (Fig 4.7c). While the supernatant of ex vivo lymph node cells shows no 
significant change in IL-17 A levels in vaccinated mice compared to controls (Fig 
4.7dl. supernatant ofDCnt and DCpm mouse lymph node cells stimulated for 3 days 
with anti-CD3/anti-CD28 contained much higher levels of IL-17 A compared to 
controls (Fig 4. 7 e). This indicates that vaccination with DCnt results in an increase 
in Thl7 and Tcl7 cells early on, while vaccination with either DCnt or DCpm results 
in an increase in the Th17 and Tc17 response at 8 weeks post-vaccination. 
DCpm vaccination results in increased levels of IL-10 at 4 weeks, while both Dent and 
DCpm vaccination results in increased levels of IL-13 at 8 weeks compared to 4NQO-
treated controls. 
Th2 cells can have inflammatory or anti-inflammatory effects, and they can 
release mUltiple different cytokines, including IL-4, IL-lO, and IL-13. These cells 
have been traditionally associated with a pro-tumorigenic phenotype. They are 
often upregulated in cancers, antagonizing a beneficial Thl response (221-224). 
However, our lab has shown that levels ofTh2 cytokines remain largely unchanged 
in the draining lymph nodes of premalignant lesion-bearing and HNSCC-bearing 
mice compared to controls (218). To evaluate the populations ofTh2 cells in 
draining lymph nodes of controt 4NQO controt DCnt, and DCpm mice, lymph node 
cells were stained for surface expression of CD4 and intracellular expression of the 
Th2 cytokines IL-4, IL-lO, and IL-13 after 4 hours incubation with PMA, Ionomycin 
and brefeldin A. In addition, supernatants of lymph node cells incubated for 4 hours 
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in PMA and Ionomycin were analyzed by cytometric bead array for levels of IL-4, IL-
la, and IL-13. At 4 weeks post-first vaccination, DCpm mice have an increased 
percentage of IL-I0 expressing CD4 T cells compared to all other groups (Fig 4.8a 
and b). This is supported by data showing an increase in IL-I0 released into the 
supernatant of ex vivo DCpm mouse lymph node cells incubated for 4 hours with 
PMA and Ionomycin compared to all other groups (Fig 4.8d). Also at this timepoint, 
DCnt mouse lymph nodes were found to have an increased absolute number of IL-
10 expressing CD4 T cells as well as an increased level of IL-l3 in supernatant of ex 
vivo lymph node cells compared to 4NQO control (Fig 4.8c and d). 
At 8 weeks post-first vaccination, DCpm mouse lymph nodes were found to 
contain a decreased percentage of IL-lO-expressing CD4 T cells compared to 4NQO 
controls and an increased number of IL-4-expressing CD4 T cells compared to 4NQO 
controls (Fig 4.8a, b, c). DCnt mouse lymph nodes have an increased percentage and 
both DCnt and DCpm mouse lymph nodes have an increased absolute number of IL-
l3-expressing CD4 T cells compared to 4NQO control (Fig 4.8c). Analysis of 
supernatant of ex vivo cells stimulated for 4 hours with PMA and Ionomycin 
revealed a significant increase in IL-l3 in both vaccinated groups compared to 
4NQO control and control (Fig 4.8d). Analysis of supernatant of cells stimulated for 
3 days with anti-CD3/anti-CD28 revealed a large increase in IL-lO, IL-l3 and IL-4 in 
supernatant from DCnt and DCpm mouse lymph node cells compared to control and 
4NQO control (Fig 4.8e). This data indicates that, while DCpm vaccination results in 
an early increase in the immunosuppressive cytokine IL-IO, both DCnt and DCpm 
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Fig 4.8 DCpm vaccination results in increased levels of IL-10 at 4 weeks, while 
both DCnt and DCpm vaccination results in increased levels of IL-13 at 8 
weeks compared to 4NQO-treated controls. 
Representative results (a) and graphical representation (b) of flow cytometric 
staining of cervical lymph node cells from control, 4NQO-treated control (4NQO Ctl), 
DCnt-vaccinated (DCnt) and DCpm-vaccinated (DCpm) mice at 4 and 8 weeks post-
first vaccination with at least 5 mice per group. Data represent mean ± SEM. *, P < 
0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Total numbers of 
populations (c) were determined by multiplying the percent positive by the number 
of cervical lymph node cells for each individual mouse. Data represent mean ± SEM. 
*, P < 0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Cytometric bead 
array analysis (d) of supernatant of 4 week and 8 week control, 4NQO Ctl, DCnt, and 
DCpm mouse cervical lymph node cells after stimulation for four hours with PMA 
and ionomycin, with at least 5 mice per group. Data represent mean ± SEM. *, P < 
0.05. **, p < 0.01. ***, P < 0.001 (2-tailed Student's t-test). Cytometric bead array 
analysis (e) of supernatant of 8 week control, 4NQO Ctl, DCnt, and DCpm mouse 
cervical lymph node cells after 3 day stimulation with anti-CD3janti-CD28 beads 
with at least 4 mice per group. Data represent mean ± SEM. *, P < 0.05 (2-tailed 
Student's t-test). 
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4.4 Discussion 
The immune reaction to tumor development is a complicated and 
multifaceted phenomenon. While the immune system is capable of recognizing and 
attacking most dysplastic tissues, some dysplastic tissue is bound to avoid 
elimination and, given time and the selective pressure of the immune system, 
variants arise which have the capacity to escape recognition and/or manipulate the 
immune system in ways which further the progression of the malignancy (225). 
This is the case with HNSCC, a cancer that is known to upregulate 
immunosuppressive cell populations such as Treg cells and promote smoldering 
inflammation through chronic upregulation of inflammatory cell types (163, 164, 
176,177,218, 219). In this study, we sought to halt the progression of HNSCC at the 
premalignant stage through dendritic cell vaccination, with the rationale that 
premalignant and HNSCC tissue share common T AAs and the immune system at the 
premalignant stage has not yet been compromised by the advanced immune-
manipulative tactics of an established tumor (136,180,218). Unexpectedly, both 
DCpm vaccination and DCnt vaccination, though to a lesser extent, resulted in a 
decrease in lesion burden compared to 4NQO treatment alone. Also, evaluation of 
lymph node cells from DCpm vaccinated mice for response to a 3 day challenge with 
premalignant or HNSCC lysate showed that a specific response was not being 
generated (Fig 4.9). Analysis of the ex vivo immune response in vaccinated mice, as 
summarized in Table 4.1, revealed an early increase in draining lymph node cell 
number and levels of stimulatory immune effectors, including activated CD4 Tconv 
cells, CDB Tconv cells, Th1, Tel, Th17, and Tc17 cells, for DCnt mice, while the 
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immune response in DCpm mice at 4 weeks mirrored that of 4NQO control mice. At 
the later timepoint, when both vaccinated groups appear to provide beneficial 
clinical effects, both DCnt and DCpm mouse lymph nodes have a greater number of 
cells, consisting ofimmunostimulatory cells such as activated CTLs, Tcl, Thl7 and 
Tcl7 cells, and, to a lesser extent, immunosuppressive Tregs and Th2 cells. These 
data indicate that DC vaccination, regardless of whether the DCs were pulsed with 
normal tongue or premalignant antigens, provides a non-specific but substantial 
immune stimulatory response and may be clinically beneficial. 
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Fig 4.9 Cervical lymph node cells from vaccinated mice do not exhibit 
specificity of reaction to premalignant lysate or UNSCC lysate challenge. 
Cytometric bead array analysis of supernatant of 4 week control, 4NQO-treated 
control (4NQO Ctl), DCnt-vaccinated (DCnt) and DCpm-vaccinated (DCpm) mouse 
cervical lymph node cells after 3 day challenge with 25 Ilg/ml of normal tongue 
epithelium lysate (NT), premalignant epithelium lysate (PM), or HNSCC lysate 
(HNSCC) in the presence of anti-CD3/anti-CD28 beads with at least 4 mice per 
group. No significant differences in IL-2 release (a), IFN-y release (b), IL-l7A 
release (c), or IL-4 release (d) were found for the different challenges within each 
mouse group (2-tailed Student's t-test). 
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This study presents the evaluation of immune response in the draining 
cervical lymph nodes of vaccinated and unvaccinated 4NQO-treated mice. This 
method of evaluation was used because the immune response to tumor is likely to 
be orchestrated in draining lymph nodes and because tongue epithelium was 
determined to contain very low numbers of T cells. However, immune response to 
treatment and to tumor development involves not only loco-regional responses, but 
also a myriad of changes in cellular localization of immune populations following 
activation. As such, it will be important to investigate immune populations present 
in tongue epithelium and in the periphery to fully determine the response to 
vaccination and tumor development. 
Evaluation of dendritic cell maturation markers and cytokines revealed no 
differences between the dendritic cells pulsed with premalignant lesion lysate and 
the dendritic cells pulsed with normal tongue epithelium lysate (Fig 4.10). 
Investigation into response to premalignant lysate or HNSCC lysate challenge 
showed no indications of specificity of reaction of DCpm mouse lymph node cells or 
DCnt mouse lymph node cells (Fig 4.9). However, DCnt vaccination clearly elicited a 
more immediate response compared to DCpm vaccination, though this did not 
correlate with a stronger clinical response compared to DCpm mice. DCpm 
vaccination, on the other hand, resulted in very little in the way of an immediate 
reaction. At the later timepoint, however, both Dent and DCpm vaccination resulted 
in increased immune stimulation and improved clinical response. Additional 
research into what delineates the different responses to these two vaccinations is 
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necessary to determine why the DCpm vaccination promotes a delayed response 
compared to the immediate response to the DCnt vaccine. 
Part of the rationale for using premalignant lesion lysate as the source of 
antigen to stimulate a specific in vivo response to premalignant and malignant tissue 
involved the over-expression of multiple common TAAs in both premalignant and 
HNSCC tissue (136, 180). However, as determined in the current study, pulsing DCs 
with premalignant antigen did not result in the development of a specific response 
of lymph node cells from vaccinated mice to premalignant or HNSCC antigens, and 
both DCnt vaccination and DCpm vaccination resulted in a similar clinical response. 
To evaluate if the clinical response seen with DCnt and DCpm vaccination is a result 
of administering activated dendritic cells regardless of pulsing with lysate, another 
control group was vaccinated with unpulsed, activated Des. Like both the Dent and 
DCpm-vaccinated groups, there was no specific response of DC-vaccinated mouse 
lymph node cells to either premalignant or HNSCC challenge (data not shown). Also, 
while DC-vaccinated mice did have a clinically significant decrease in lesion burden, 
there was no difference in lesion burden between the DC-vaccinated and DCnt- or 
DCpm-vaccinated groups (data not shown). Therefore, it is likely that the clinical 
benefit seen is solely due to an increase in numbers of activated Des. These 
activated Des may pick up antigen after injection into the tongue, resulting in cross-
presentation to cytotoxic T cells. It is also possible that in using tissue lysate as an 
antigenic source, the extraneous components of the lysate prevented sufficient 
stimulation of cells with the intended premalignant and HNSCC tissue-associated 
T AAs. Future experimentation into vaccination of mice with specific T AA-pulsed 
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Fig 4.10 Dendritic cells have the same expression of costimulatory markers 
and cytokines whether pulsed with normal tongue epithelium lysate or 
premalignant epithelium lysate. 
Immature bone marrow-derived dendritic cells were pulsed with lysates of 
premalignant epithelium (DCpm vaccine) or normal tongue epithelium (DCnt 
vaccine), then matured with LPS. Phenotyping of dendritic cells by flow 
cytometric staining (a) and cytometric bead array (b) of at least 4 separate 
experiments reveal no significant differences between dendritic cell maturation 
markers or cytokines between the two groups (2-tailed Student's t-test). 
DCs may lead to the development of an immunotherapy providing a specific immune 
response with improved clinical benefit. 
HNSCC is an aggressive malignancy that has a complicated relationship with 
the immune system. The development of immunotherapeutic strategies to combat 
this cancer is highly important to increasing the poor survival rate of patients with 
HNSCC. While the dendritic cell vaccination described in this study reduced lesion 
burden by only a small amount, the immune system interactions described help to 
advance our understanding of the functions of various immune cell subtypes during 
the development of HNSCC. Further investigation into the intricacies of the tumor-
immune system relationship will allow for more efficient development of 
treatments that have a better chance of being effective in the future. 
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Tconv Th17/Tc17 Th2 
C04+ C08+ C04+ C08+ C04+ C08+ C04+ 




4NQO C08+ C04+ C08+ C02S+ C044hi C08+ C04+ C08+ C04+ 
Control) Foxp3" Foxp3+ Foxp3+ C08Tconv CD4 IFN-y+ Il-17A+ Il-17A+ Il-4+ 
DCnt ~ ~ ~ ~ ~ ~ ~ ~ 
DCpm ~ ~ ~ ~ ~ ~ ~ 
Table 4.1 Summary of significant differences in absolute numbers of cell 
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CHAPTER 5: GENERAL DISCUSSION 
5.1 Implications of Immune Response During HNSee Development 
In the theory of immunoediting, there are three stages of immune response 
during tumor development: elimination .. equilibrium, and escape. Elimination 
involves an anti-tumor response in which Thl and Tcl cells direct immune 
effectors, including CTLs and macrophages, to clear dysplastic tissue (1, 2). 
Equilibrium involves the co-evolution of tumor variants with the immune system, 
often resulting in the emergence of non-immunogenic tumor variants that have 
gained the ability to subvert the immune system through several mechanisms, a 
stage referred to as escape (2, 17-19). However, the immune system can also 
contribute to tumor development through the effects of unresolved chronic 
inflammation (105-111). The mediators that promote tumor growth often overlap 
with the mediators that combat tumor growth} complicating the classification of 
certain immune responses as U anti-tuIDor" or ((pro-tumor.1I Careful investigation 
into the intricacies of immune responses to the development of specific cancers is 
essential to determining the true roles of the immune cells in these cancers. 
HNSCC is a cancer that has been shown to have a complicated relationship 
with the immune system. As such, this study aimed to further elucidate the 
implications of the immune alterations observed in HNSCC by examining the 
immune responses during HNSCC development. HNSCC is somewhat unique in that, 
with vigilant surveillance, it may be identified in its premalignant stages as 
leukoplakia or erythroplakia of the oral mucosa (173). Analysis of these 
premalignant lesions in humans and mice revealed an increase in inflammatory 
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cytokine levels, such as IFN-y, compared to control tissue. Analysis of the draining 
cervical lymph nodes in premalignant lesion-bearing mice also revealed an increase 
in stimulatory immune effectors from Tconv cells bearing markers of activation and 
memory to Thl, Tel, and Th17 cells compared to control lymph nodes. However, no 
significant differences were found in systemic levels of any evaluated cytokines 
between control plasma and plasma from patients bearing premalignant lesions. 
This data indicates that, at the stage at which premalignant lesions become 
detectable, a strong local inflammatory immune response, with no accompanying 
immunosuppression} has been mounted. 
While the data clearly indicates that the premalignant stage of HNSCC 
development is associated with a strong inflammatory immune response, the role of 
the response is still unclear. Classical thought would indicate that the observed 
response is part of an anti-tumor immune reaction that, in the case of 4NQO-treated 
mice, is unable to eliminate the dysplastic effects of ongoing carcinogen treatment. 
However, it is also possible that the observed inflammatory response is partially 
responsible for continued progression towards cancer. Further investigation into 
the roles of these cells through models involving oncogenesis in IFN -y, IL-17 A, CD4, 
or CDS knockout mice will serve to uncover the beneficial or detrimental effects of 
each of the immune cell types during tumor development. 
5.2 Complexity of HNSCC-Associated Immune Response 
The classic description of immune escape involves downregulation of 
immunogenic properties, the skewing of a type I response to a type II response, and 
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an upregulation of multiple immune inhibitory factors, such as regulatory T cells 
(2). Past research indicates that HNSCC follows this model in several ways, 
including a downregulation of MHC class I molecules and B7 molecules, an 
upregulation ofTh2 cytokines, and a large increase in peripheral and tumor-
infiltrating Tregs (28, 143-145, 163, 164). The present study sought to further 
investigate the locoregional immune alterations in established HNSCC using both a 
mouse model of 4NQO-induced carcinogenesis and human samples. While we did 
observe the expected increase in Treg cells in cervical lymph nodes of HNSCC-
bearing mice compared to control, there was also an increase in levels of 
conventional T cells found in lymph nodes of HNSCC-bearing mice compared to 
control. In addition, there was an unexpected increase in Thl cells in cervical lymph 
nodes of HNSCC-bearing mice compared to control mice. Human tumor samples 
had a similar increase in levels of IFN-y compared to normal/adjacent control tissue. 
This data indicates that, contrary to past research, an inflammatory reaction 
involving Thl cells continues in the setting of established HNSCC. 
The Th1 reaction observed in mice with established HNSCC could have 
several implications. It is conceivable that this response may represent an ongoing 
attempt at an anti-tumor response whose effects are simply overwhelmed by the 
multitude of other immune manipulative factors induced by the tumor. Conversely, 
it is possible that this response, and the Th1 and Tcl response observed at the 
premalignant stage, is tumor promoting. Though generally associated with an anti-
tumor response, IFN-y expression and Thl cells have been linked to tumor 
promotion in several studies, most notably in carcinogen-induced tumors of 
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epithelial origin similar to 4NQO-induced or tobacco smoking~induced HNSCC 
development (120, 121). Thirdly, the Thl and Tel response observed at the 
premalignant stage may be representative of a beneficial immune response} while 
the Thl and Tel response at the HNSCC stage may be representative ofa 
detrimental immune response. In cervical lymph nodes of premalignant lesion-
bearing mice, there is a higher increase in the percentage of Tcl cells than Thl cells} 
while HNSCC-bearing mice have a higher increase in the percentage ofThl cells 
than Tcl cells. In addition, premalignant lesion-bearing mice have a much greater 
percentage of Th17 cells compared to HNSCC-bearing mice. It is possible that the 
Tel and Th 17 cells at the premalignant stage are working together in a concerted 
effort to combat oncogenesis, while the shift towards Thl cells and decrease in Th17 
cells with a simultaneous increase in Tregs represents a completely separate, pro-
oncogenic immune reaction at the HNSCC stage. 
Established HNSCC was found to be associated with an increase in both 
Teonv cells and Tregs. Further analysis revealed that Teonv cells from HNSCC-
bearing mice have a reduced proliferative capacity compared to Teonv cells from 
control mice, providing somewhat of an explanation for how these stimulatory cells 
could co-exist with what was expected to be an immunosuppressive 
microenvironment. In addition .. analysis of the Treg cells showed that, 
unexpectedly} Tregs from HNSCC-bearing miee suppress Tconv cells to a lesser 
degree than Tregs from control mice .. It will be important in the future to determine 
any other role these Tregs may be playing in the HNSCC microenvironment, as they 
appear to lose their primary function ofT cell suppression as the tumor progresses. 
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5.3 Immunotherapy at the Premalignant Stage 
The rationale for initiation of immunotherapy at the premalignant stage of 
HNSCC development included the fact that oral lesions are identifiable at the 
premalignant stage, premalignant lesions and HNSCC share overexpression of 
common tumor antigens, and the hypothesis that the premalignant stage of HNSCC 
development would not be associated with the systemic immunosuppression that 
past studies identified in patients with HNSCC (136, 173, 180). Our data showing 
that both mice and humans with premalignant lesions experience a local increase in 
inflammatory immune mediators without any immunosuppression supported our 
reasoning behind initiation of immunotherapy at this point. In this study, 
premalignant lysate-pulsed dendritic cells were administered to mice bearing 
premalignant lesions in an attempt to halt or even reverse the progression of these 
lesions to HNSCC. Unexpectedly, lymphocytes from DCpm mice did not show any 
specificity of reaction to premalignant or HNSCC lysate challenge. However, both 
DCpm vaccination and vaccination with the control vaccine were associated with a 
decrease in lesion burden compared to unvaccinated, 4NQO-treated controls. 
Analysis of draining cervical lymph node cells from vaccinated mice revealed that 
DCnt vaccination resulted in an early increase in levels of stimulatory immune 
effectors compared to DCpm and 4NQO control mice, while DCpm vaccination 
resulted in a delayed increase in levels of stimulatory immune effectors compared to 
4NQO control mice. This data indicated that activated Des were capable of 
generating a non-specific immune stimulatory response associated with improved 
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clinical prognosis regardless of the whether the Des were pulsed with normal 
tongue or premalignant antigens. With this large increase in the non-specific 
immune stimulatory response in mind, it is important to evaluate levels of 
additional possible contributory cells, such as N K cells, N KT cells, and yS T cells, to 
the anti-tumor response in future studies. 
Evaluation of dendritic cell maturation markers and cytokines revealed no 
significant differences between dendritic cells pulsed with normal tongue 
epithelium lysate or premalignant epithelium lysate, and evaluation of lymphocytes 
from DCnt and DCpm mice revealed no specificity of response to normal tongue 
epithelium lysate, premalignant epithelium lysate, or HNSCC lysate challenge. 
However, DCpm vaccination was found to reduce lesion burden two weeks earlier 
than Dent vaccination, and Dent vaccination was found to increase multiple 
stimulatory immune effectors at the 4 week point, while DCpm vaccination was not 
associated with an increase in these effectors until the 8 week point. Additional 
research into the differing consequences of pulsing dendritic cells with normal 
tongue epithelium lysate versus premalignant lesion lysate is necessary to 
determine what is responsible for the differing responses to the two vaccines. 
Tumor lysate is often used as a source of antigen for dendritic cell 
vaccination because it allows sensitization to mUltiple potentially immunogenic 
TAAs simultaneously, a method that is especially helpful when the most 
immunogenic TAAs expressed by the tumor tissue have not yet been identified 
(226-228). Premalignant lesion lysate was used for the antigenic source for pulsing 
dendritic cells for vaccination because previous studies showed that both 
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premalignant lesions and HNSCC overexpress several of the same tumor antigens, 
though the immunogenicity of each individual antigen has not yet been determined 
(136, 180). The current study showed that, contrary to expectations, vaccination 
with premalignant lesion-lysate pulsed dendritic cells did not result in the 
development of a specific immune response to premalignant or HNSCC epithelium. 
It is possible that components of the lysate, aside from TAAsJ may block or even 
suppress sensitization of Des to the intended TAAs (229,230). As such, future 
experimentation using specific antigens} rather than premalignant tissue lysate, to 
pulse dendritic cells prior to vaccine administration may result in the successful 
development of a specific response with increased clinical benefit. 
5.4 Closing Remarks 
The current study presented the evaluation of immune responses to the 
development of HNSCC in carcinogen-treated mice and humans. Experimentation 
revealed that the premalignant stage is associated with a rise in inflammatory 
immune effectors without immunosuppression .. while established HNSCC is 
associated with a seemingly contradictory rise in both immunosuppressive and 
immunostimulatory populations. The genuine roles of the evaluated immune 
effectors have yet to be established; future experimentation involving carcinogen-
treatment of mice lacking expression of these individual cell populations is 
necessary to determine the anti-tumor versus pro-tumorigenic functions of these 
populations. The elucidation of these links will provide much-needed information 
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for the tailoring of future immune therapies aimed at combatting or preventing the 
development of HNSCC. 
The current study also evaluated the feasibility of initiating immunotherapy 
at the premalignant stage of HNSCC development} thus avoiding the obstacle of 
systemic immunosuppression seen in established HNSCC} specifically through the 
use of premalignant antigens in a dendritic cell vaccine. Both the experimental 
DCpm vaccine and the control DCnt vaccine resulted in clinical benefit to 
carcinogen-treated mice, even without the development of a specific response to 
premalignant or HNSCC antigens} a result that is both unexpected and promising. 
Future investigation involving optimization of dendritic cell preparation .. perhaps 
using specific TAAs as an antigen source, will allow for more efficient development 
of treatments that have an increased opportunity of being clinically effective and 
may eventually be used in the clinic to combat this notoriously highly aggressive 
and tenacious malignancy. 
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